var title_f38_21_39248="Pediatric coronoid fracture classification";
var content_f38_21_39248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediatric coronoid fracture classification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Type I: Avulsion of the tip of the coronoid.",
"    <br>",
"     (B) Type II: A single or somminuted fragment involving &le;50 percent of the coronoid process.",
"     <br>",
"      (C) Type III: A single or comminuted fragment involving &gt;50 percent of the coronoid process.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39248=[""].join("\n");
var outline_f38_21_39248=null;
var title_f38_21_39249="Patient information: Preterm premature rupture of membranes (The Basics)";
var content_f38_21_39249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/2/4131\">",
"         Patient information: How to tell when labor starts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/20/27970\">",
"         Patient information: Preterm labor (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/52/35650\">",
"         Patient information: Preterm labor (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preterm premature rupture of membranes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preterm-premature-rupture-of-membranes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2362919\">",
"      <span class=\"h1\">",
"       What is preterm premature rupture of membranes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The medical term for when a woman&rsquo;s water breaks is &ldquo;rupture of membranes.&rdquo; Premature rupture of membranes is when a woman&rsquo;s water breaks before she goes into labor. Doctors and midwives call premature rupture of membranes &ldquo;PROM&rdquo; for short. &ldquo;Preterm&rdquo; PROM is when this happens when a pregnancy is less than 37 weeks.",
"     </p>",
"     <p>",
"      Preterm PROM is a problem because labor often begins soon after it happens. Babies who are born before 37 weeks of pregnancy are premature. Premature babies can have serious health problems.",
"     </p>",
"     <p>",
"      PROM can also lead to problems in the mother. For example, it can lead to an infection in the uterus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362934\">",
"      <span class=\"h1\">",
"       What causes preterm PROM?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors aren&rsquo;t sure why preterm PROM happens in some women and not others. But preterm PROM is more likely to happen in women who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Had preterm PROM before",
"       </li>",
"       <li>",
"        Had preterm labor and delivery before",
"       </li>",
"       <li>",
"        Have an infection in the vagina or uterus",
"       </li>",
"       <li>",
"        Have bleeding from the vagina",
"       </li>",
"       <li>",
"        Smoke",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362949\">",
"      <span class=\"h1\">",
"       What are the symptoms of preterm PROM?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When a woman&rsquo;s water breaks, it can feel like a sudden gush or a slow trickle of fluid from the vagina. The fluid is clear or pale yellow and sometimes looks like urine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362964\">",
"      <span class=\"h1\">",
"       Is there a test for preterm PROM?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor, nurse, or midwife will use a speculum to examine your cervix. He or she will look to see if amniotic fluid is leaking from your cervix. He or she will also take a sample of the fluid in your vagina, look at it under a microscope, and test it with special paper. This is to make sure the fluid is amniotic fluid.",
"     </p>",
"     <p>",
"      Your doctor or midwife might also do an ultrasound exam to check the amount of amniotic fluid around your baby. An ultrasound is an imaging test that uses sound waves to create pictures of your baby in your uterus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362979\">",
"      <span class=\"h1\">",
"       How is preterm PROM treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Almost all women with preterm PROM need to stay in the hospital until their baby is born. That&rsquo;s so their doctor or midwife can follow their pregnancy closely.",
"     </p>",
"     <p>",
"      In many cases, labor starts within 1 week of preterm PROM.",
"     </p>",
"     <p>",
"      If your labor doesn&rsquo;t start on its own, your doctor or midwife might give you medicine to help start it. This is called inducing labor. Your doctor or midwife is more likely to induce labor if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are 34 or more weeks pregnant, and your baby&rsquo;s lungs are developed.",
"       </li>",
"       <li>",
"        You are less than 34 weeks pregnant, but there is a problem with your pregnancy or your baby&rsquo;s health. The most common problem that might happen is an infection in the uterus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your doctor or midwife doesn&rsquo;t deliver your baby right away, he or she might treat you with medicines, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines called &ldquo;steroids&rdquo; to help your baby breathe better when he or she is born. (These steroids are different from the ones athletes take to build muscle.)",
"       </li>",
"       <li>",
"        Antibiotics to prevent an infection",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362994\">",
"      <span class=\"h1\">",
"       Will my baby be OK?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on many factors, such as how early your baby is born, how developed his or her lungs are, and whether he or she has an infection. Babies who are born very early are more likely to have health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2363009\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=see_link\">",
"       Patient information: Preterm labor (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/2/4131?source=see_link\">",
"       Patient information: How to tell when labor starts (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=see_link\">",
"       Patient information: Preterm labor (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/21/39249?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82972 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39249=[""].join("\n");
var outline_f38_21_39249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362919\">",
"      What is preterm premature rupture of membranes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362934\">",
"      What causes preterm PROM?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362949\">",
"      What are the symptoms of preterm PROM?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362964\">",
"      Is there a test for preterm PROM?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362979\">",
"      How is preterm PROM treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362994\">",
"      Will my baby be OK?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2363009\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39250="Patient information: Bladder cancer (The Basics)";
var content_f38_21_39250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15351\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/9/37011\">",
"          How urine leaves the body after the bladder is removed",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/12/31939\">",
"         Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/54/15205\">",
"         Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/39/13939\">",
"         Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/53/10066\">",
"         Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bladder cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bladder-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H48238817\">",
"      <span class=\"h1\">",
"       What is bladder cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bladder cancer happens when normal cells in the bladder change into abnormal cells, and grow out of control (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). Bladder cancer is more common in men and in older people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238824\">",
"      <span class=\"h1\">",
"       What are the symptoms of bladder cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bladder cancer does not usually cause symptoms. When symptoms do occur, they can come and go and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood in the urine, which makes your urine look pink or red",
"       </li>",
"       <li>",
"        Pain on the sides of your back or above your pubic area",
"       </li>",
"       <li>",
"        Pain when urinating, urinating often, or leaking urine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not bladder cancer. But if you see blood in your urine, you should be checked by a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238831\">",
"      <span class=\"h1\">",
"       Is there a test for bladder cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can use different types of tests to look for bladder cancer. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Urine tests",
"        </strong>",
"        &ndash; Urine tests can show what kind of cells are in the urine.",
"       </li>",
"       <li>",
"        <strong>",
"         X-rays, CT scans, or other imaging tests",
"        </strong>",
"        &ndash; These tests create images of your urinary tract. They can show tumors or abnormal growths.",
"       </li>",
"       <li>",
"        <strong>",
"         Cystoscopy",
"        </strong>",
"        &ndash; Cystoscopy is a procedure that allows the doctor to look inside the bladder. To do a cystoscopy, the doctor inserts a small tube into the urethral opening, the opening through which urine leaves the body. Then he or she threads the tube up into the bladder. The tube has a tiny camera that projects images of the bladder onto a screen. If the doctor sees anything unusual, he or she might take a sample of tissue (biopsy) to look at under the microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238838\">",
"      <span class=\"h1\">",
"       What is bladder cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your cancer. Your treatment will also depend on your age and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238845\">",
"      <span class=\"h1\">",
"       How is bladder cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with bladder cancer often have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Bladder cancer is usually treated with surgery that can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Taking out the cancer and leaving the bladder in place. In many cases, this is done through cystoscopy.",
"       </li>",
"       <li>",
"        Taking out the cancer and a part of the bladder. After this surgery, people can often urinate normally and have normal sexual function.",
"       </li>",
"       <li>",
"        Taking out the cancer, the bladder, and nearby internal organs. This surgery can damage the nerves that control sexual function.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. These medicines can go either into a vein or directly into your bladder. Some people get these medicines before surgery to shrink the cancer and make it easier to remove. People might also receive these medicines after surgery to keep the cancer from growing, spreading, or coming back.",
"       </li>",
"       <li>",
"        <strong>",
"         Other therapy",
"        </strong>",
"        &ndash; Another type of medicine for bladder cancer goes directly into the bladder. This medicine is different than chemotherapy. It teaches your body&rsquo;s infection-fighting system to attack cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238852\">",
"      <span class=\"h1\">",
"       If my bladder is taken out, where will my urine go?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During surgery, your doctor will create a new way for urine to leave your body (",
"      <a class=\"graphic graphic_figure graphicRef79286 \" href=\"mobipreview.htm?36/9/37011\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238859\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow up tests can include urine tests, cystoscopy, and x-rays.",
"     </p>",
"     <p>",
"      Tell your doctor or nurse if you have any of the symptoms listed above. Having those symptoms could mean the cancer has come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238866\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more surgery, or get chemotherapy or radiation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238873\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for bladder cancer involves making many choices, such as which type of surgery to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H48238880\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/12/31939?source=see_link\">",
"       Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/39/13939?source=see_link\">",
"       Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=see_link\">",
"       Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/21/39250?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15351 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39250=[""].join("\n");
var outline_f38_21_39250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238817\">",
"      What is bladder cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238824\">",
"      What are the symptoms of bladder cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238831\">",
"      Is there a test for bladder cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238838\">",
"      What is bladder cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238845\">",
"      How is bladder cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238852\">",
"      If my bladder is taken out, where will my urine go?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238859\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238866\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238873\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48238880\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/9/37011\">",
"       How urine leaves the body after the bladder is removed",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/12/31939?source=related_link\">",
"      Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=related_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/39/13939?source=related_link\">",
"      Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39251="Nerve conduction studies: Late responses";
var content_f38_21_39251=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nerve conduction studies: Late responses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39251/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39251/contributors\">",
"     Steven H Horowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39251/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39251/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39251/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39251/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/21/39251/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unique natural electrical properties of peripheral nerves can be evaluated in health and disease with externally applied stimuli and analysis of the consequent neurophysiologic responses. Nerve conduction study techniques permit stimulation and recording of electrical activity from individual peripheral nerves with sufficient accuracy, reproducibility, and standardization to determine normal values, characterize abnormal findings, and correlate neurophysiologic-pathologic features.",
"   </p>",
"   <p>",
"    These clinical studies are used to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnose focal and generalized disorders of peripheral nerves",
"     </li>",
"     <li>",
"      Classify peripheral nerve conduction abnormalities due to axonal degeneration, demyelination, and conduction block",
"     </li>",
"     <li>",
"      Prognosticate regarding clinical course and efficacy of treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the late responses (the F waves and H reflex). The late responses are most useful for studying the proximal segments, the plexus and nerve roots, of the peripheral nervous system.",
"   </p>",
"   <p>",
"    The clinical study of nerve conduction is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Needle electromyography is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     F WAVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depolarizing peripheral nerves with external stimuli evoke potentials that propagate both proximally and distally. With motor nerves, electrical activity moving distally (orthodromically) results in a direct motor response, the compound muscle action potential (CMAP), also known as the M response. Electrical activity propagating proximally (antidromically) activates a small percentage of motor neurons (they \"backfire\"), which then can generate another wave known as the F wave (also called the F response). The F wave is visible as a low amplitude late potential following the M response (",
"    <a class=\"graphic graphic_waveform graphicRef75038 \" href=\"mobipreview.htm?1/45/1744\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pathway of electrical activity along a motor nerve that ultimately results in a recordable F wave is initially antidromic to the motor neuron, and then orthodromic from the motor neuron, traversing the motor nerve axon through terminal nerve branches, synapses, and muscle fibers. The F wave latency incorporates the conduction times through each of these components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Current physiologic evidence supports this concept of an antidromic and then orthodromic motor neuron pathway, although early theories postulated reflex activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    F waves are recorded using surface electrodes over distal muscles and supramaximal nerve stimulation in the same manner as motor nerve conduction studies, except that the stimulating cathode is proximal to the anode to prevent anodal block of the antidromic potential. However, the value of reversing the orientation of the stimulus for obtaining F waves has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antidromic neural activity can trigger an orthodromic action potential in the same motor neuron by reactivating its initial segment, or axon hillock. Several physiologic phenomena can prevent all motor neurons from being activated with each nerve stimulus, including prolonged refractory periods at the axon hillock, inhibition of recurrent collaterals from motor neuron to motor neuron, and activation of Renshaw interneurons that inhibit smaller motor neurons. These same phenomena reduce the chance of eliciting an F wave with every nerve stimulus, despite the stimulus being supramaximal. Those neurons that do contribute to the F wave may be the largest and fastest conducting myelinated motor fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observable single F waves result from activation of one to, at most, a few motor neurons, and each F wave results from activation of different subpopulations of motor neurons with each stimulation. This inconsistency in motor neuron activation accounts for the variability in F wave configuration, amplitude, and latency during a series of stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, it is important to record at least 10 to 20 F waves for analysis.",
"   </p>",
"   <p>",
"    Analysis of the following F wave parameters is clinically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean latency, rather than the shortest latency",
"     </li>",
"     <li>",
"      Chronodispersion, the difference between minimal and maximal latencies",
"     </li>",
"     <li>",
"      Mean amplitude in relation to the maximum M potential (the mean",
"      <span class=\"nowrap\">",
"       F/M",
"      </span>",
"      amplitude ratio)",
"     </li>",
"     <li>",
"      Persistence of the F wave, defined as the percentage of stimuli in a series that results in a recordable F wave (normally &gt;50 percent, and usually 80 to 100 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical utility of F waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;F waves are of particular value in peripheral neuropathies with predominant proximal involvement, such as acute and chronic inflammatory demyelinating polyneuropathies, in which distal conduction velocities may be normal early in the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    F wave minimal latencies of &gt;120 percent of the upper limit of normal (&gt;150 percent if the distal negative peak CMAP amplitude was &lt;80 percent of the lower limit of normal) in each of two nerves indicate primary demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Lesser degrees of F wave slowing may be seen in axonal and mixed polyneuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/4\">",
"     4",
"    </a>",
"    ]. Nevertheless, F wave slowing appears to be highly sensitive for nerve pathology in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/8\">",
"     8",
"    </a>",
"    ]. In demyelinating polyneuropathies, there is decreased persistence of F waves with absent F waves in the presence of relatively preserved M responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of F waves in focal nerve lesions, such as radiculopathy, is controversial. The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) concluded that F waves in isolation cannot definitively diagnose radiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/9\">",
"     9",
"    </a>",
"    ]. F wave conduction along longer normal nerve segments may \"dilute\" any conduction delay across much shorter radicular segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/1\">",
"     1",
"    </a>",
"    ]. Since most peripheral nerves consist of axons from multiple nerve roots, with multiple innervation of the muscles undergoing recording, normal conductivity across unaffected roots may also dilute the abnormalities of the affected root.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     H REFLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The H reflex is a monosynaptic (or, at most, an oligosynaptic) reflex. The afferent arc is mediated by large, fast-conducting group 1a fibers, and the efferent arc is mediated by alpha motor neurons with muscle fiber activation. As such, the neural circuitry is identical to the stretch, or tendon, reflex but bypasses the muscle spindles and gamma-motor system.",
"   </p>",
"   <p>",
"    After infancy, the H reflex is most consistently seen with tibial nerve stimulation in the popliteal fossa when recording from the soleus and plantar foot muscles, and less consistently obtained with median nerve stimulation when recording from the flexor carpi radialis. As with tendon reflexes, the H reflex can be enhanced by contraction of the recording muscle and depressed by contraction of antagonist muscles. The soleus H reflex decreases in amplitude with age but can be elicited in 92 percent of healthy people who are age 60 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/10\">",
"     10",
"    </a>",
"    ]. The typical soleus H reflex latency is approximately 30 msec; the upper limit of normal is 35 msec.",
"   </p>",
"   <p>",
"    As opposed to the F wave, the H reflex is visible only with submaximal stimulation (",
"    <a class=\"graphic graphic_figure graphicRef81004 \" href=\"mobipreview.htm?29/53/30558\">",
"     figure 1",
"    </a>",
"    ). With a slow increase in stimulus strength, the H reflex appears as the stimulus changes from subthreshold to submaximal. The amplitude of the H reflex is greatest just below the threshold for the appearance of the compound muscle action potential (CMAP) or M response. With increasing stimulus strength, the H reflex amplitude declines as M response amplitude increases. The H reflex disappears with maximal and supramaximal stimulation, replaced by the F wave, which has a slightly longer latency.",
"   </p>",
"   <p>",
"    Stimulus durations of 0.5 to 1.0 msec are necessary for group 1a afferent fiber activation. As with the F wave, the stimulating cathode is proximal to the anode. Several mechanisms may account for the decline and extinction of the H reflex with increasing stimulus strength, including collision of the orthodromic potential from the motor neuron with antidromic activity along the motor axon from the stimulus site, refractoriness of the motor neuron axon hillock, and Renshaw inhibition of the motor neuron pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical utility of H reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The H reflex is most commonly used to assess the S1 nerve root in suspected radiculopathies and proximal conduction in polyneuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/11\">",
"     11",
"    </a>",
"    ]. Unilateral absence of the H reflex or side-to-side differences of &gt;1.5 to 2.0 msec support a focal nerve lesion on the affected side, most commonly at the S1 root, but also at the sacral plexus or sciatic nerve. Because it is a reflex, the H reflex can also be used to study central nervous system functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39251/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      F waves are late responses generated by supramaximal nerve stimulation (",
"      <a class=\"graphic graphic_waveform graphicRef75038 \" href=\"mobipreview.htm?1/45/1744\">",
"       waveform 1",
"      </a>",
"      ). Electrical activity moving proximally in motor nerves activates or backfires motor neurons, which can generate an orthodromic response known as the F wave that is visible as a low amplitude late potential. F waves are useful for evaluating peripheral neuropathies with predominantly proximal involvement. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'F waves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The H reflex is a true reflex with an afferent arc mediated by large, fast-conducting group 1a fibers, and an efferent arc mediated by alpha motor neurons (",
"      <a class=\"graphic graphic_figure graphicRef81004 \" href=\"mobipreview.htm?29/53/30558\">",
"       figure 1",
"      </a>",
"      ). It is visible only with submaximal stimulation and is most consistently seen with tibial nerve stimulation in the popliteal fossa when recording from the soleus and plantar foot muscles. The H reflex is useful for evaluating the S1 nerve root in suspected radiculopathies and proximal conduction in polyneuropathies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'H reflex'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kimura, J. Electrodiagnosis in Diseases of Nerve and Muscle, 3rd ed, Oxford University Press, Oxford 2001.",
"    </li>",
"    <li>",
"     Dumitru, D. Electrodiagnostic Medicine, Hanlye &amp; Belfus, Philadelphia, PA 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/3\">",
"      Young MS, Triggs WJ. Effect of stimulator orientation on F-wave persistence. Muscle Nerve 1998; 21:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/4\">",
"      Fisher MA. F-waves--physiology and clinical uses. ScientificWorldJournal 2007; 7:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/5\">",
"      Kiers L, Clouston P, Zuniga G, Cros D. Quantitative studies of F responses in Guillain-Barr&eacute; syndrome and chronic inflammatory demyelinating polyneuropathy. Electroencephalogr Clin Neurophysiol 1994; 93:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/6\">",
"      Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/7\">",
"      Van den Bergh PY, Pi&eacute;ret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004; 29:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/8\">",
"      Andersen H, St&aring;lberg E, Falck B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve 1997; 20:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/9\">",
"      American Association of Neuromuscular &amp; Electrdiagnostic Medicine (AANEM). Proper performance and interpretation of electrodiagnostic studies. Muscle Nerve 2006; 33:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/10\">",
"      Falco FJ, Hennessey WJ, Goldberg G, Braddom RL. H reflex latency in the healthy elderly. Muscle Nerve 1994; 17:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/11\">",
"      Cho SC, Ferrante MA, Levin KH, et al. Utility of electrodiagnostic testing in evaluating patients with lumbosacral radiculopathy: An evidence-based review. Muscle Nerve 2010; 42:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39251/abstract/12\">",
"      Misiaszek JE. The H-reflex as a tool in neurophysiology: its limitations and uses in understanding nervous system function. Muscle Nerve 2003; 28:144.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5146 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39251=[""].join("\n");
var outline_f38_21_39251=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      F WAVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical utility of F waves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      H REFLEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical utility of H reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5146|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/53/30558\" title=\"figure 1\">",
"      H reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5146|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?1/45/1744\" title=\"waveform 1\">",
"      F waves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39252="Pipotiazine: Patient drug information";
var content_f38_21_39252=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pipotiazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/44/36550?source=see_link\">",
"     see \"Pipotiazine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Piportil&reg; L",
"      <sub>",
"       4",
"      </sub>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change the electrical activity in your heart. This change could cause fast heartbeats. This drug does not mix well with many drugs. Check all drugs with your doctor before starting this drug. If you have a history of fast heartbeats, tell your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pipotiazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease, brain problem, very bad heart disease, kidney disease, liver disease, low blood count, or low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11089 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39252=[""].join("\n");
var outline_f38_21_39252=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210521\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025008\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025010\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025009\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025014\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025015\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025017\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025012\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025013\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025018\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025019\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/44/36550?source=related_link\">",
"      Pipotiazine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39253="Floxuridine: Drug information";
var content_f38_21_39253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Floxuridine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/43/20148?source=see_link\">",
"    see \"Floxuridine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      FUDR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal or gastric metastases:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intra-arterial:",
"     </i>",
"     Primarily by an implantable pump: 0.1-0.6 mg/kg/day continuous intra-arterial administration for 14 days then heparinized saline is given for 14 days; toxicity requires dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (unlabeled use):",
"     </i>",
"     Many regimens in use, examples:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.15 mg/kg/day for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.5-1 mg/kg/day for 6-15 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     30 mg/kg/day for 5 days, then 15 mg/kg/day every other day, up to 11 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjust dose since elderly patients are prone to toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines; use with extreme caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5527395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines; use with extreme caution. The following guidelines have been used by some clinicians (Floyd, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum bilirubin 1.2 times ULN or alkaline phosphatase 1.2 times ULN: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum bilirubin 1.5 times ULN; transaminases 3 times baseline or alkaline phosphatase 1.5 times ULN: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum bilirubin 2 times ULN; transaminases &gt;3 times baseline or alkaline phosphatase 2 times ULN: No recommendation is available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous intra-arterial or I.V. infusion (unlabeled use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F171632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, aztreonam, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, melphalan, ondansetron, paclitaxel, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, cefepime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hepatic metastases of colorectal and gastric cancers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Floxuridine may be confused with Fludara&reg;, fludarabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FUDR&reg; may be confused with Fludara&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis, diarrhea; may be dose limiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression, may be dose limiting; leukopenia, thrombocytopenia, anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Onset: 4-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nadir: 5-9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recovery: 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, photosensitivity, hyperpigmentation of the skin, localized erythema, dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Biliary sclerosis, cholecystitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% {Limited to important or life-threatening): Nausea, vomiting, intrahepatic abscess",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Poor nutritional states, depressed bone marrow function, potentially serious infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity: Discontinue if intractable vomiting, diarrhea, precipitous fall in leukocyte or platelet counts,  myocardial ischemia, hemorrhage, gastrointestinal ulcer, or stomatitis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Use with caution in patients with depressed (leukocyte count &lt;5000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) bone marrow function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Use with caution in patients with potentially serious infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alkylating agents: Use with caution in patients who have had previous use of alkylating agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pelvic radiation recipients: Use with caution in patients who have had high-dose pelvic radiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Poor nutritional status: Use with caution in patients with poor nutritional status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]:  Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initiation of therapy:",
"     <b>",
"      [U.S. Boxed Warning]: Patients should be hospitalized for initiation of the first course of therapy due to the risk for severe toxic reactions.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Floxuridine may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Floxuridine may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Medications that  inhibit DNA synthesis are known to be teratogenic in humans. Women of childbearing potential should avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13817230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     It is not known if floxuridine is excreted in human milk; the manufacturer recommends against breast-feeding during floxuridine treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Floxuridine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 g (1): $142.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13361477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, platelet count, liver function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      FUDR (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism of action and pharmacokinetics are very similar to fluorouracil; floxuridine is the deoxyribonucleotide of fluorouracil. Floxuridine is a fluorinated pyrimidine antagonist which inhibits DNA and RNA synthesis and methylation of deoxyuridylic acid to thymidylic acid.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; Active metabolites: Floxuridine monophosphate (FUDR-MP) and fluorouracil; Inactive metabolites: Urea, CO",
"     <sub>",
"      2",
"     </sub>",
"     , &alpha;-fluoro-&beta;-alanine, &alpha;-fluoro-&beta;-guanidopropionic acid, &alpha;-fluoro-&beta;-ureidopropionic acid, and dihydrofluorouracil",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine: Fluorouracil, urea, &alpha;-fluoro-&beta;-alanine, &alpha;-fluoro-&beta;-guanidopropionic acid, &alpha;-fluoro-&beta;-ureidopropionic acid, and dihydrofluorouracil; exhaled gases (CO",
"     <sub>",
"      2",
"     </sub>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Davidson BS, Izzo F, Chase JL, et al, &ldquo;Alternating Floxuridine and 5-Fluorouracil Hepatic Arterial Chemotherapy for Colorectal Liver Metastases Minimizes Biliary Toxicity,&rdquo;",
"      <i>",
"       Am J Surg",
"      </i>",
"      , 1996, 172(3):244-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39253/abstract-text/8862076/pubmed\" id=\"8862076\" target=\"_blank\">",
"        8862076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeConti RC, Kaplan SR, Papac RJ, et al, &ldquo;Continuous Infusions of 5-Fluoro-2-Deoxyuridine in the Treatment of Solid Tumors,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1973, 31(4):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39253/abstract-text/4267531/pubmed\" id=\"4267531\" target=\"_blank\">",
"        4267531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Takats PG, Kerr DJ, Poole CJ, et al, &ldquo;Hepatic Arterial Chemotherapy for Metastatic Colorectal Carcinoma,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1994, 69(2):372-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39253/abstract-text/8297738/pubmed\" id=\"8297738\" target=\"_blank\">",
"        8297738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39253/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hrushesky WJ, von Roemeling R, Lanning RM, et al, &ldquo;Circadian-Shaped Infusions of Floxuridine for Progressive Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, 8(9):1504-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39253/abstract-text/2144018/pubmed\" id=\"2144018\" target=\"_blank\">",
"        2144018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kemeny N, Seiter K, Conti JA, et al, Hepatic Arterial Floxuridine and Leucovorin for Unresectable Liver Metastases From Colorectal Carcinoma. New Dose Schedules and Survival Update,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1994, 73(4):1134-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8942 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39253=[""].join("\n");
var outline_f38_21_39253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708773\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171607\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171627\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171610\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171611\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171612\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527395\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171588\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171575\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171591\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171632\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171589\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171633\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171625\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171594\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171579\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299341\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171583\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171602\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171585\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206852\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171618\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817230\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323153\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361477\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171596\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171578\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171593\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/43/20148?source=related_link\">",
"      Floxuridine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39254="Vitamin B6 (pyridoxine): Drug information";
var content_f38_21_39254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B6 (pyridoxine): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/38/33380?source=see_link\">",
"    see \"Vitamin B6 (pyridoxine): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/60/33733?source=see_link\">",
"    see \"Vitamin B6 (pyridoxine): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aminoxin&reg; [OTC];",
"     </li>",
"     <li>",
"      Pyri-500 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral (IOM, 1998):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-50 years: 1.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;51 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 1.7 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy: 1.9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary deficiency:",
"     </b>",
"     I.M., I.V.: 10-20 mg/day for 3 weeks, followed by oral therapy. Doses up to 600 mg/day may be needed with pyridoxine dependency syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of peripheral neuropathy associated with isoniazid therapy for",
"     </b>",
"     <b>",
"      <i>",
"       Mycobacterium tuberculosis:",
"      </i>",
"     </b>",
"     Oral:  25-50 mg/day (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of nausea and vomiting of pregnancy (unlabeled use):",
"     </b>",
"     Oral: 10 to 25 mg every 8 hours (Neibyl, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of isoniazid-induced seizures and/or coma (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute ingestion of known amount:",
"     </i>",
"     Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 5 g); administer at a rate of 0.5-1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4-6 hours (Howland, 2006; Morrow, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute ingestion of unknown amount:",
"     </i>",
"     Initial: 5 g; administer at a rate of 0.5-1 g/minute; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland, 2006; Morrow, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of isoniazid-induced seizures and/or coma (unlabeled use):",
"     </b>",
"     I.V.: Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Boyer, 2006). Dosing recommendations are the same as for the treatment of symptomatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of seizures from acute Gyromitrin-containing mushroom toxicity (unlabeled use; Diaz, 2005):",
"     </b>",
"     I.V.: 25 mg/kg over 15-30 minutes; repeat dose as needed to control seizures",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/60/33733?source=see_link\">",
"      see \"Vitamin B6 (pyridoxine): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate Intake (AI):",
"     </b>",
"     Oral (IOM, 1998): Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 0.1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 0.3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral (IOM, 1998): Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 0.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 1.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of isoniazid-induced seizures and/or coma (unlabeled use):",
"     </b>",
"     I.V.: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute ingestion of known amount:",
"     </i>",
"     Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 70 mg/kg, up to 5 g); administer at a rate of 0.5-1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4-6 hours (Howland, 2006; Morrow, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute ingestion of unknown amount:",
"     </i>",
"     Initial: 70 mg/kg (maximum dose: 5 g); administer at a rate of 0.5-1 g/minute; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland, 2006; Morrow, 2006; Santucci, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of isoniazid-induced seizures and/or coma (unlabeled use):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of seizures from acute Gyromitrin-containing mushroom toxicity (unlabeled use; Diaz, 2005):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 50 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminoxin&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 200 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 25 mg, 50 mg, 100 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyri-500: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Burning may occur at the injection site after I.M. or SubQ administration; seizures have occurred following I.V. administration of very large doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Isoniazid toxicity (unlabeled use): Initial doses should be administered at a rate of 0.5-1 g/minute. If the parenteral formulation is not available, anecdotal reports suggest that pyridoxine tablets may be crushed and made into a slurry and given at the same dose orally or via nasogastric (NG) tube (Boyer, 2006). Oral administration is not recommended for acutely poisoned patients with seizure activity.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F216047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of vitamin B",
"     <sub>",
"      6",
"     </sub>",
"     deficiency",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5509480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prophylaxis of neurological toxicities (ie, seizures, coma) associated with isoniazid and Gyromitrin-containing mushroom (false morel) overdose/toxicity; nausea and vomiting of pregnancy; prevention of peripheral neuropathy associated with isoniazid therapy for",
"     <i>",
"      Mycobacterium tuberculosis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pyridoxine may be confused with paroxetine, pralidoxime, Pyridium&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Brazil] may be confused with Doxil brand name for DOXOrubicin [U.S.]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal: Brand name for pyridoxine/thiamine combination [Brazil], but also the brand name for doxepin [Finland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, seizure (following very large I.V. doses), somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, folic acid decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuropathy, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyridoxine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Warnings related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Severe, permanent peripheral neuropathies have been reported; neurotoxicity is more common with long-term administration of large doses (&gt;2 g/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Some parenteral products contain aluminum; use caution in patients with impaired renal function and neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dependence/withdrawal: Doses &gt;200 mg/day may cause dependence and withdrawal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pharmacy supply of emergency antidotes: Guidelines suggest that at least 8-24 g be stocked. This is enough to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period. In areas where tuberculosis is common, hospitals should consider stocking 24 g. This is enough to treat 1 patient for 24 hours (Dart, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin deficiency: Single vitamin deficiency is rare; evaluate for other deficiencies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F215989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta. Maternal pyridoxine plasma concentrations may decrease as pregnancy progresses and requirements may be increased in pregnant women (IOM, 1998). Pyridoxine is used to treat nausea and vomiting of pregnancy (Neibyl, 2010). In addition to being a dietary supplement, pyridoxine is also used as an antidote. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F215990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyridoxine is found in breast milk and concentrations vary by maternal intake. Pyridoxine requirements are increased in nursing women compared to non-nursing women (IOM, 1998). Possible inhibition of lactation at doses &gt;600 mg/day when taken immediately postpartum (Foukas, 1973).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F215988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pyridoxine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (1 mL): $11.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pyridoxine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $3.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $4.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $3.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5509499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For treatment of isoniazid or Gyromitrin-containing mushroom toxicity: Anion gap, arterial blood gases, electrolytes, neurological exam, seizure activity",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F215978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Over 50 ng/mL (SI: 243 nmol/L) (varies considerably with method). A broad range is ~25-80 ng/mL (SI: 122-389 nmol/L). HPLC method for pyridoxal phosphate has normal range of 3.5-18 ng/mL (SI: 17-88 nmol/L).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F215991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AFI-B6 (NO);",
"     </li>",
"     <li>",
"      Alertasa (ES);",
"     </li>",
"     <li>",
"      B(6)-Vicotrat (DE);",
"     </li>",
"     <li>",
"      Becilan (FR);",
"     </li>",
"     <li>",
"      Bedoxine (BE, LU);",
"     </li>",
"     <li>",
"      Bedoyecta (MX);",
"     </li>",
"     <li>",
"      Beesix (ZA);",
"     </li>",
"     <li>",
"      Beglunina (ES);",
"     </li>",
"     <li>",
"      Benadon (AR, AT, CH, ES, GB, IE, IT, PT, SE);",
"     </li>",
"     <li>",
"      Bexivit (GR);",
"     </li>",
"     <li>",
"      Biprin (CO);",
"     </li>",
"     <li>",
"      Bivit (IT);",
"     </li>",
"     <li>",
"      Burgerstein Vitamin B!6 (CH);",
"     </li>",
"     <li>",
"      Comploment Continus (AE, BH, CH, CY, EG, IE, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Conductasa (ES);",
"     </li>",
"     <li>",
"      Dermo 6 (FR);",
"     </li>",
"     <li>",
"      Dermo Chabre B6 (ES);",
"     </li>",
"     <li>",
"      Dextamina B6 (ES);",
"     </li>",
"     <li>",
"      Dodemina (MX);",
"     </li>",
"     <li>",
"      Dolo Bedoyecta (MX);",
"     </li>",
"     <li>",
"      Dolvifen (MX);",
"     </li>",
"     <li>",
"      Farmobion B6 (IT);",
"     </li>",
"     <li>",
"      Glutarase (IT);",
"     </li>",
"     <li>",
"      Godabion B6 (ES);",
"     </li>",
"     <li>",
"      Heksavit (FI);",
"     </li>",
"     <li>",
"      Hexobion 100 (DE);",
"     </li>",
"     <li>",
"      Hysix (JP);",
"     </li>",
"     <li>",
"      Incremin con hierro (MX);",
"     </li>",
"     <li>",
"      M. V. I. 12 (MX);",
"     </li>",
"     <li>",
"      Memosprint (IT);",
"     </li>",
"     <li>",
"      Natele (MX);",
"     </li>",
"     <li>",
"      Nuro-B (MX);",
"     </li>",
"     <li>",
"      Pharmaton (MX);",
"     </li>",
"     <li>",
"      Pidopidon (JP);",
"     </li>",
"     <li>",
"      Piridoxina Austral (AR);",
"     </li>",
"     <li>",
"      Piriglutina (ES);",
"     </li>",
"     <li>",
"      Plivit B6 (HR);",
"     </li>",
"     <li>",
"      Poly-B con Vitamina C (MX);",
"     </li>",
"     <li>",
"      Pyricontin Continus (IN);",
"     </li>",
"     <li>",
"      Pyridoxin Recip[Tab.] (SE);",
"     </li>",
"     <li>",
"      Pyridoxin &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Pyridoxine Aguettant (FR);",
"     </li>",
"     <li>",
"      Pyridoxine Renaudin (FR);",
"     </li>",
"     <li>",
"      Pyridoxine-Labaz (LU);",
"     </li>",
"     <li>",
"      Pyrivitol (AT);",
"     </li>",
"     <li>",
"      Pyroxin (AU);",
"     </li>",
"     <li>",
"      Reisevit (AT);",
"     </li>",
"     <li>",
"      Sechvitan (JP);",
"     </li>",
"     <li>",
"      Serfoxide (ES);",
"     </li>",
"     <li>",
"      Tanvimil B6 (AR);",
"     </li>",
"     <li>",
"      Trineurovita (MX);",
"     </li>",
"     <li>",
"      Vit. B6 Agepha (AT);",
"     </li>",
"     <li>",
"      Vita-B6 (FI);",
"     </li>",
"     <li>",
"      Vitamin B!6 (HU);",
"     </li>",
"     <li>",
"      Vitamin B!6 Streuli (CH);",
"     </li>",
"     <li>",
"      Vitamine B!6 Richard (FR);",
"     </li>",
"     <li>",
"      Vitaminum B6 (PL);",
"     </li>",
"     <li>",
"      Xanturenasi (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Precursor to pyridoxal, which functions in the metabolism of proteins, carbohydrates, and fats; pyridoxal also aids in the release of liver and muscle-stored glycogen and in the synthesis of GABA (within the central nervous system) and heme",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Enteral, parenteral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to pyridoxal phosphate and pyridoxamine phosphate (active forms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biologic: 15-20 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Albin RL, Albers JW, Greensberg HS, et al, &ldquo;Acute Sensory Neuropathy - Neuronopathy From Pyridoxine Overdose,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1987, 37(11):1729-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/2823181/pubmed\" id=\"2823181\" target=\"_blank\">",
"        2823181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baxter P, \"Epidemiology of Pyridoxine Dependent and Pyridoxine Responsive Seizures in the UK,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1999, 81(5):431-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/10519720/pubmed\" id=\"10519720\" target=\"_blank\">",
"        10519720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW, &ldquo;Antituberculous Medications,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 8th ed, Flomenbaum NE, Goldfrank LR, Hoffman, RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2006, 861-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase P, Walter F, Vandenberghe D, et al, &ldquo;Pyridoxine Does Not Prevent Hyperbaric Oxygen Toxicity Seizures in Rats,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):531.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC, Borron SW, Caravati EM, et al,&ldquo;Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2009, 54(3):386-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/19406507/pubmed\" id=\"19406507\" target=\"_blank\">",
"        19406507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Zegher FD, Przyrembel H, Chalmers RA, et al, &ldquo;Successful Treatment on Infantile Type I Primary Hyperoxaluria Complicated by Pyridoxine Toxicity,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1985, 2(8451):392-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diaz JH, &ldquo;Syndromic Diagnosis and Management of Confirmed Mushroom Poisonings,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2005, 33(2):427-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/15699849/pubmed\" id=\"15699849\" target=\"_blank\">",
"        15699849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foukas MD, \"An Antilactogenic Effect of Pyridoxine,\"",
"      <i>",
"       J Obstet Gynaecol BrCommonw",
"      </i>",
"      , 1973, 80(8):718-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/4579974/pubmed\" id=\"4579974\" target=\"_blank\">",
"        4579974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glenn GM, Krober MS, Kelly P, et al, &ldquo;Pyridoxine as Therapy in Theophylline-Induced Seizures,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1995, 37(4):342-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/8540225/pubmed\" id=\"8540225\" target=\"_blank\">",
"        8540225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greentree LB, \"Inhibition of Prolactin by Pyridoxine,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1979, 135(2):280-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/474683/pubmed\" id=\"474683\" target=\"_blank\">",
"        474683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harati Y and Niakan E, &ldquo;Hydrazine Toxicity, Pyridoxine Therapy, and Peripheral Neuropathy,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1986, 104(5):728-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Pyridoxine,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 8th ed, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2006, 872-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      </i>",
"      <sub>",
"       6",
"      </sub>",
"      <i>",
"       , Folate, Vitamin B",
"      </i>",
"      <sub>",
"       12",
"      </sub>",
"      <i>",
"       , Pantothenic Acid, Biotin, and Choline",
"      </i>",
"      , Washington, DC: The National Academies Press, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kajiyama Y, Fujii K, Takeuchi H, et al, &ldquo;Ginko Seed Poisoning,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 109(2):325-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/11826216/pubmed\" id=\"11826216\" target=\"_blank\">",
"        11826216",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LoVecchio F, Curry SC, Graeme KA, et al, &ldquo;Intravenous Pyridoxine-Induced Metabolic Acidosis,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2001 38(1):62-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/11423814/pubmed\" id=\"11423814\" target=\"_blank\">",
"        11423814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morrow LE, Wear RE, Schuller D, et al, \"Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(10):1529-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/16999664/pubmed\" id=\"16999664\" target=\"_blank\">",
"        16999664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagappan R and Riddell T, &ldquo;Pyridoxine Therapy in a Patient With Severe Hydrazine Sulfate Toxicity,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000, 28(6):2116-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/10890675/pubmed\" id=\"10890675\" target=\"_blank\">",
"        10890675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niebyl JR, \"Clinical Practice. Nausea and Vomiting in Pregnancy,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(16):1544-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/20942670/pubmed\" id=\"20942670\" target=\"_blank\">",
"        20942670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orlowski JP, Paganini EP, Pippenger CE, et al, &ldquo;Treatment of a Potentially Lethal Dose Isoniazid Ingestion,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1988, 17(1):73-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/3337420/pubmed\" id=\"3337420\" target=\"_blank\">",
"        3337420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pauling L, &ldquo;Sensory Neuropathy From Pyridoxine Abuse,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(3):197-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/6318110/pubmed\" id=\"6318110\" target=\"_blank\">",
"        6318110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santucci KA, Shah BR, and Linakis JG, \"Acute Isoniazid Exposures and Antidote Availability,\"",
"      <i>",
"       Pediatric Emergency Care",
"      </i>",
"      , 1999, 15(2):99-101.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharman EJ and Rosencrane JG, &ldquo;Isoniazid Toxicity: A Survey of Pyridoxine Availability,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(3):386-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schnyder G, Roffi M, Flammer Y, et al, &ldquo;Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Clinical Outcome After Percutaneous Coronary Intervention: The Swiss Heart Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(8):973-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/21/39254/abstract-text/12190367/pubmed\" id=\"12190367\" target=\"_blank\">",
"        12190367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9839 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39254=[""].join("\n");
var outline_f38_21_39254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216001\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216041\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216003\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216023\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216004\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215977\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215962\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215982\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216047\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215981\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5509480\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216049\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216039\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215966\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299968\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215971\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215974\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215989\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216007\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215990\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215988\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5509499\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215978\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215991\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215965\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215985\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/38/33380?source=related_link\">",
"      Vitamin B6 (pyridoxine): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/60/33733?source=related_link\">",
"      Vitamin B6 (pyridoxine): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39255="Diagnosis of epidermolysis bullosa";
var content_f38_21_39255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of epidermolysis bullosa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Anna L Bruckner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Dedee F Murrell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Susan J Bayliss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39255/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/21/39255/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2394277\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa (EB) comprises a heterogeneous group of inherited disorders with the common finding of epithelial fragility. The skin, and in some cases the mucosa, develops blisters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosions in response to minimal frictional trauma. Four major EB types are recognized on the basis of the ultrastructural level of skin cleavage (",
"    <a class=\"graphic graphic_figure graphicRef52111 \" href=\"mobipreview.htm?7/20/7493\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EB simplex (intraepidermal)",
"     </li>",
"     <li>",
"      Junctional EB (intra-lamina lucida)",
"     </li>",
"     <li>",
"      Dystrophic EB (sub-lamina densa) &nbsp;",
"     </li>",
"     <li>",
"      Kindler syndrome (intraepidermal, intra-lamina lucida and sub-lamina densa)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical, pathophysiological, and molecular criteria define more than 30 subtypes of EB (",
"    <a class=\"graphic graphic_table graphicRef77709 graphicRef67202 graphicRef55262 graphicRef81536 \" href=\"mobipreview.htm?27/19/27955\">",
"     table 1A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the diagnosis of EB. The pathogenesis, clinical features, and management of EB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3066?source=see_link\">",
"     \"Overview of the management of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2394284\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT EB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa (EB) should be suspected in individuals presenting with a history of recurrent blistering or erosions with onset in infancy or childhood. A family history of similar manifestations is supportive. The skin changes usually are localized to areas of trauma but are out of proportion to the degree of trauma. EB should be considered in any neonate who presents with blisters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosions in the absence of another plausible etiology (eg, infection). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link\">",
"     \"Vesiculobullous and pustular lesions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older children and adults, scarring, milia, nail dystrophy, oral involvement, or other organ involvement may suggest the EB subtype. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036886823\">",
"    <span class=\"h2\">",
"     Other causes of blistering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating EB from other blistering diseases may be difficult, especially in newborns. In older children and adults, the timing of onset of blistering helps in distinguishing EB from autoimmune bullous diseases. In some cases, clinical or laboratory features may confirm a diagnosis other than EB (eg, sucking blisters and infection), but skin biopsy is generally necessary to confirm the other disorders. &nbsp;",
"   </p>",
"   <p>",
"    In neonates and young infants, congenital or acquired disorders that should be considered in the differential diagnosis of EB include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bullous congenital ichthyosiform erythroderma (epidermolytic ichthyosis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H8#H8\">",
"       \"The genodermatoses\", section on 'Epidermolytic ichthyosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Incontinentia pigmenti (",
"      <a class=\"graphic graphic_picture graphicRef58769 \" href=\"mobipreview.htm?12/38/12897\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H29839499#H29839499\">",
"       \"The genodermatoses\", section on 'Incontinentia pigmenti'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aplasia cutis congenita (",
"      <a class=\"graphic graphic_picture graphicRef77708 \" href=\"mobipreview.htm?15/27/15794\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=see_link&amp;anchor=H21#H21\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Aplasia cutis congenita'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Focal dermal hypoplasia (",
"      <a class=\"graphic graphic_picture graphicRef55714 \" href=\"mobipreview.htm?23/52/24386\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H34#H34\">",
"       \"The genodermatoses\", section on 'Focal dermal hypoplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital erythropoietic porphyria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5801?source=see_link\">",
"       \"Congenital erythropoietic porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bullous mastocytosis (",
"      <a class=\"graphic graphic_picture graphicRef52257 \" href=\"mobipreview.htm?43/7/44145\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\", section on 'Diffuse cutaneous mastocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neonatal pemphigus vulgaris and pemphigoid gestationis (transient, transplacentally acquired conditions seen in newborns born to mothers with the disorders). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29657?source=see_link&amp;anchor=H2#H2\">",
"       \"Dermatoses of pregnancy\", section on 'Pemphigoid gestationis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral and bacterial infections, including herpes simplex, bullous impetigo, and staphylococcal scalded skin syndrome (",
"      <a class=\"graphic graphic_picture graphicRef81483 graphicRef59762 graphicRef72261 \" href=\"mobipreview.htm?11/48/12042\">",
"       picture 5A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link&amp;anchor=H4#H4\">",
"       \"Vesiculobullous and pustular lesions in the newborn\", section on 'Herpes simplex'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link&amp;anchor=H8#H8\">",
"       \"Vesiculobullous and pustular lesions in the newborn\", section on 'Staphylococcal scalded skin syndrome'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Sucking blisters (",
"      <a class=\"graphic graphic_picture graphicRef67302 \" href=\"mobipreview.htm?17/47/18161\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link&amp;anchor=H21#H21\">",
"       \"Vesiculobullous and pustular lesions in the newborn\", section on 'Congenital sucking blisters'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In older children and adults some autoimmune bullous diseases may share clinical features with EB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linear IgA disease (chronic bullous disease of childhood (",
"      <a class=\"graphic graphic_picture graphicRef62298 graphicRef76142 \" href=\"mobipreview.htm?35/52/36680\">",
"       picture 7A-B",
"      </a>",
"      ) and adult linear IgA disease (",
"      <a class=\"graphic graphic_picture graphicRef56434 \" href=\"mobipreview.htm?15/62/16359\">",
"       picture 8",
"      </a>",
"      )). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14922?source=see_link\">",
"       \"Linear IgA bullous dermatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bullous pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef58359 \" href=\"mobipreview.htm?15/29/15827\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidermolysis bullosa acquisita (EBA) (",
"      <a class=\"graphic graphic_picture graphicRef62505 \" href=\"mobipreview.htm?21/36/22085\">",
"       picture 10",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/47/4858?source=see_link\">",
"       \"Epidermolysis bullosa acquisita\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these acquired disorders, the blisters usually occur near the time of presentation. However, in EB, blistering generally begins in early infancy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2394291\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211650349\">",
"    <span class=\"h2\">",
"     Overview of approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy for immunofluorescence microscopy (IFM) is the first step in the diagnosis of epidermolysis bullosa (EB). IFM is sufficient for diagnosis if it identifies the level or cleavage and the subtype; this occurs in most cases. If IFM is normal or fails to demonstrate the level of cleavage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subtype, the diagnosis can be confirmed with either transmission electron microscopy (TEM) or mutational analysis. If possible, a venous blood sample should be obtained at the initial visit (or consultation in the neonatal unit); it should be stored to allow subsequent DNA extraction in the event that mutational analysis becomes necessary.",
"   </p>",
"   <p>",
"    Many local laboratories are able to determine the type of EB, based on the cleavage level determined by immunohistochemistry with antibodies to collagen IV and keratin 14. However, the accurate identification of the EB subtype is performed only in specialized laboratories and requires IFM with specific monoclonal antibodies (mAb) targeting EB-specific proteins, TEM, or mutational analysis. Identifying and contacting the laboratory before the biopsy is performed will ensure that the specimen is obtained and processed appropriately. Information on the centers for the diagnosis and treatment of EB is available from the website of the Dystrophic EB Research Association (DebRA)-International at",
"    <a class=\"external\" href=\"file://www.debra-international.org\">",
"     www.debra-international.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22232119\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected EB should undergo skin biopsy of an induced blister for IFM; TEM may be necessary if IFM is inconclusive or normal. Although TEM may not be necessary in some cases, it is most practical to perform biopsies for both studies at the same time. IFM and TEM identify the level of skin cleavage, morphologic alterations of epithelial adhesion structures in the basement membrane zone, and defective expression of adhesion proteins at the dermal-epidermal junction.",
"   </p>",
"   <p>",
"    Routine histology of an EB lesion typically shows a non-inflammatory intra- or subepidermal blister and is not helpful in establishing the EB type. However, routine histology may be useful to exclude other etiologies of bullous or erosive lesions, particularly in the neonate. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link\">",
"     \"Vesiculobullous and pustular lesions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2394298\">",
"    <span class=\"h3\">",
"     Obtaining biopsies for EB diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper technique is critical when biopsying for EB diagnosis since submission of suboptimal specimens (eg, due to no blister, no epidermis, or reepithelialization) is a relatively common reason why IFM",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    TEM cannot be performed or do not yield a diagnosis. Accurate interpretation of IFM and TEM requires examination of fresh blisters. When blisters are more than 12 hours old, proteolytic antigen degradation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    re-epithelialization under the roof of the blister may result in artifactual cleavage planes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/2\">",
"     2",
"    </a>",
"    ]. A fresh blister is usually induced in an area of skin that is clinically uninvolved but adjacent to a site where the patient usually blisters. The palms and soles should be avoided because the increased skin thickness in these areas makes the identification of the cleavage site difficult. To avoid unnecessary repetition of the procedure, it is important that the fresh blister is induced by a clinician with expertise in EB.",
"   </p>",
"   <p>",
"    Administration of topical anesthetics (such as EMLA under occlusion) before local anesthesia should be avoided because topical anesthetics may induce artificial blistering, especially in the epidermis.",
"   </p>",
"   <p>",
"    After identifying the biopsy site, the area is prepared in a sterile manner and outlined. Experts disagree as to the optimal agent for producing the blister; a cotton-swab, pencil eraser, or gloved finger or thumb may be used. Firm downward pressure is applied to the skin and a traction is then exerted by twisting (at least 180 degrees each way), until erythema is produced (the biopsy site is re-cleaned after the blister is induced) (",
"    <a class=\"graphic graphic_picture graphicRef60027 \" href=\"mobipreview.htm?6/27/6581\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/3\">",
"     3",
"    </a>",
"    ]. The amount of friction necessary to induce a subclinical blister may vary from patient to patient, but the development of erythema at the site is a good endpoint. For newborns or infants, a reasonable rule of thumb is to rub the selected area at least 20 times.",
"   </p>",
"   <p>",
"    For patients with milder skin fragility, up to two minutes of induced friction can be necessary to induce the blister. It may be helpful to ask older children or adults with milder skin fragility to perform an activity that induces a fresh blister before a clinic appointment for biopsy.",
"   </p>",
"   <p>",
"    A biopsy of unaffected, non-rubbed skin may be required in patients with extreme mechanical skin fragility (a characteristic feature of recessive EB). In these patients, performing a punch biopsy may be sufficient to induce the cleavage plane necessary for diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies are performed at least five minutes after the induction of erythema to allow the development of a microscopically identifiable blister. The biopsy site is cleaned with an antiseptic solution (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    stings less than alcohol) and draped. Two separate biopsies from adjacent sites are taken. Most laboratories prefer punch biopsies over shave biopsies because punched specimens are easier to orient and embed for frozen sections. Approximately one-third to one-half of each biopsy should include the induced blister, with the remaining portion comprised of unaffected skin. A larger biopsy may be split in two, but this procedure is not recommended since it might separate the epidermis from the dermis with loss of the diagnostic cleavage plane.",
"   </p>",
"   <p>",
"    Biopsies should be sent to a laboratory experienced in the diagnosis of EB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/1\">",
"     1",
"    </a>",
"    ]. Identifying and contacting the laboratory before the biopsy is performed will ensure that the specimen is obtained and processed appropriately. Information on the centers for the diagnosis and treatment of EB is available from the website of the Dystrophic EB Research Association (DebRA)-International at",
"    <a class=\"external\" href=\"file://www.debra-international.org\">",
"     www.debra-international.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For IFM, a three or four mm biopsy is immersed immediately in Michel&rsquo;s transport medium (ammonium sulfate, N-ethyl-maleimide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , potassium citrate buffer, and distilled water; the correct pH buffering is important) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/4\">",
"     4",
"    </a>",
"    ]. It is essential to avoid contamination of the IFM sample with formalin or TEM fixative to preserve antigen expression.",
"   </p>",
"   <p>",
"    For TEM, a two mm biopsy is placed in 2.5% glutaraldehyde solution (glutaraldehyde buffered by 0.1 M sodium cacodylate, pH 7.4) and stored at 4&deg;C before shipping overnight at either room temperature or with a cold pack if ambient temperatures are greater than 37&deg;C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2394305\">",
"    <span class=\"h3\">",
"     Immunofluorescence microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunofluorescence microscopy (IFM) mapping of induced blisters has superseded TEM as the diagnostic investigation of choice for EB because of its wide availability, rapid turnaround time, lower cost, and higher degrees of sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blister mapping by IFM is performed in many local laboratories and involves the use of a limited number of antibodies directed against basement membrane antigens, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bullous pemphigoid antigen-1 (BP 230)",
"     </li>",
"     <li>",
"      Laminin-332",
"     </li>",
"     <li>",
"      Collagen IV",
"     </li>",
"     <li>",
"      Keratin 14",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These antibodies map the corresponding antigens in relation to the blister and allow the diagnosis of three of the four major EB types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In EB simplex, in which blistering occurs within the epidermis, all these antibodies will stain only the floor of the blister.",
"     </li>",
"     <li>",
"      In junctional EB, in which blistering occurs within the lamina lucida, anti-laminin 332 and anti-BP-230 will stain the roof of the blister (if present), whereas anti-collagen IV will stain the floor.",
"     </li>",
"     <li>",
"      In dystrophic EB, all antibodies will stain only the roof of the blister, indicating that the cleavage plain is below the lamina densa. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with suspected Kindler syndrome should undergo mutational analysis. (See",
"    <a class=\"local\" href=\"#H4214194\">",
"     'Mutational analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of the EB subtype by IF mapping is performed in specialized laboratories and involves the use of panels of specific monoclonal antibodies that target EB-specific proteins of the dermal-epidermal junction. A panel of EB-specific monoclonal antibodies (mAb) and their corresponding proteins is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef67732 \" href=\"mobipreview.htm?29/7/29819\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The determination of the patient&rsquo;s underlying molecular defect is based upon the staining intensity (normal, reduced, or absent) of EB-specific proteins. Absent or attenuated staining of specific proteins is diagnostic for a specific EB subtype. As an example, in severe recessive dystrophic EB (DEB), the staining of type VII collagen is absent, whereas in other generalized or localized subtypes of DEB the expression of type VII collagen is reduced or variable (",
"    <a class=\"graphic graphic_table graphicRef62232 \" href=\"mobipreview.htm?1/56/1933\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information on centers for the diagnosis and treatment of EB is available from the website of the Dystrophic EB Research Association (DebRA)-International at",
"    <a class=\"external\" href=\"file://www.debra-international.org\">",
"     www.debra-international.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22232179\">",
"    <span class=\"h3\">",
"     Transmission electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission electron microscopy (TEM) has historically been the initial diagnostic test for EB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/7\">",
"     7",
"    </a>",
"    ]. However, several drawbacks limit its widespread use now that IFM is available: it is time-consuming, labor-intensive, expensive, operator-dependent, potentially more subjective in its interpretation, and available only in a few specialized centers. However, TEM may be helpful for determining the level of skin separation and is used in some instances to confirm or refine the diagnosis obtained by immunofluorescence mapping (IFM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/8\">",
"     8",
"    </a>",
"    ]. As an example, in milder forms of EB, particularly those inherited in a dominant manner, IFM may be normal, whereas TEM can identify microsplits and other ultrastructural abnormalities at the dermal-epidermal junction.",
"   </p>",
"   <p>",
"    <br/>",
"    TEM utilizes a magnification of 3000 to 30,000X, which allows the visualization of the level of skin cleavage and morphology of the structural components of the dermal-epidermal junction, including keratin intermediate filaments, hemidesmosomes, and anchoring fibrils. TEM is of particular use in diagnosing EB simplex Dowling-Meara, a subtype of EB simplex. In this form of EB, IFM may show no abnormality, except an intraepidermal split, whereas TEM demonstrates the characteristic aggregation of keratin intermediate filaments in the basal keratinocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=see_link&amp;anchor=H2900707#H2900707\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Epidermolysis bullosa simplex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2394319\">",
"    <span class=\"h3\">",
"     Diagnostic accuracy of IFM and TEM analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few small studies have evaluated the accuracy of TEM and IFM in the diagnosis of EB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/5,9,10\">",
"     5,9,10",
"    </a>",
"    ]. In the only study that used a gold standard (genetic testing), the sensitivity and specificity of TEM were 71 and 81 percent and the sensitivity and specificity of IFM with an expanded panel of 13 monoclonal antibodies (mAbs) were 97 and 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2394326\">",
"    <span class=\"h2\">",
"     Genetic diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4214194\">",
"    <span class=\"h3\">",
"     Mutational analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutational analysis for genetic diagnosis is not recommended as a first line test for EB diagnosis because of the large genetic heterogeneity (at least 15 genes have been implicated), high cost, long turn-around time, and limited availability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. However, in the event that mutational analysis may be necessary at some point in the future, it is desirable to obtain and store a venous blood sample at the initial visit (or consultation in the neonatal unit) to allow subsequent DNA extraction. Ideally, a blood sample is obtained in an EDTA tube and sent to a genetics laboratory for genomic DNA extraction and storage. Many laboratories are able to work with as little as 2 or 2.5 mL of blood. Contacting the laboratory to discuss feasibility and requirements before obtaining the specimen is advised.",
"   </p>",
"   <p>",
"    Mutational analysis is labor intensive because subtypes of EB may not be associated with mutational hotspots and sequencing of an entire gene or multiple genes is often required.",
"   </p>",
"   <p>",
"    The sensitivity of mutation analysis ranges from 60 to 95 percent and depends upon the affected gene and techniques used for analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4214201\">",
"    <span class=\"h3\">",
"     Indications for mutational analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutational analysis is usually performed as a confirmatory test after the candidate genes have been identified by IFM",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    TEM. However, it may be part of the initial evaluation in the following scenarios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with suspected Kindler syndrome (KS). The identification of the mutations in the",
"      <em>",
"       FERMT1",
"      </em>",
"      gene is the diagnostic gold standard for KS, since IFM for kindlin-1 is unreliable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In newborns who are the first affected members in the family, since EB subtype and inheritance pattern are not clear and a precise diagnosis is important to evaluate the prognosis and for genetic counseling.",
"     </li>",
"     <li>",
"      In patients with milder forms of dystrophic EB (DEB), in whom the distinction between a localized, recessive DEB and a de novo, dominant form is not possible on the basis of the clinical phenotype and TEM or IFM findings. Family history is not useful in these cases because parents are not affected and other siblings may be unaffected as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In families with a severely affected child, when prenatal diagnosis or preimplantation genetic diagnosis are planned for subsequent pregnancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061030\">",
"    <span class=\"h3\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is increasingly sought by families with children affected by the most severe forms of EB, including recessive dystrophic EB, junctional EB-Herlitz, and EB with pyloric atresia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutational analysis is the standard of care for prenatal diagnosis and has superseded the techniques involving the ultrastructural examination of fetal skin biopsy samples. Before any prenatal test, DNA samples from both parents and any affected siblings are analyzed for causative mutations. This initial screening determines the pattern of inheritance and establishes the reliability of the prenatal test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For prenatal diagnosis, fetal DNA is obtained from chorionic villi (in the first trimester of pregnancy) or amniotic cells (after 15 weeks) and analyzed for mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The validity of DNA-based prenatal diagnosis is high; in one series of 144 pregnancies at risk for EB, the outcome was discordant from the prediction in only three cases (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22232763\">",
"    <span class=\"h3\">",
"     Preimplantation genetic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preimplantation genetic diagnosis (PGD) is a highly specialized procedure available in a limited number of centers worldwide. In this procedure, genetic testing is performed three days after in-vitro fertilization, at the 6 to 10 cell stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/19\">",
"     19",
"    </a>",
"    ]. The genetic diagnosis is performed on a single cell and suitable embryos can be transferred to the uterus on day four or five of development. A PGD protocol for Herlitz junctional epidermolysis bullosa has been developed, validated, and successfully used in a clinical case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of PGD, including a discussion of limitations and safety, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590744\">",
"    <span class=\"h3\">",
"     Specialized laboratories for genetic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on specialized centers for the diagnosis of EB is available from the website of the Dystrophic EB Research Association (DebRA)-International at",
"    <a class=\"external\" href=\"file://www.debra-international.org\">",
"     www.debra-international.org",
"    </a>",
"    . In the United States, a single commercial laboratory (GeneDX, Gaithersburg, MD) performs genetic testing for most forms of EB. Worldwide, genetic testing is offered at a few diagnostic or research laboratories, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39255/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beutner Laboratories:",
"      <a class=\"external\" href=\"file://www.beutnerlabs.com/\">",
"       www.beutnerlabs.com",
"      </a>",
"      (for immunofluorescence mapping)",
"     </li>",
"     <li>",
"      Gene Dx:",
"      <a class=\"external\" href=\"file://www.genedx.com/\">",
"       www.genedx.com",
"      </a>",
"     </li>",
"     <li>",
"      EB Center Freiburg:",
"      <a class=\"external\" href=\"file://www.netzwerk-eb.de/\">",
"       www.netzwerk-eb.de",
"      </a>",
"     </li>",
"     <li>",
"      Laboratory for Molecular Therapy, eb house Austria, Department of Dermatology, University Hospital Salzburg, M&uuml;llner Hauptstr, 48, 5020 Salzburg",
"     </li>",
"     <li>",
"      Department of Human Genetics, Radboud University Medical Center Nijmegen, Netherlands (for",
"      <em>",
"       COL7A1",
"      </em>",
"      testing):",
"      <a class=\"external\" href=\"file://www.dnadiagnostieknijmegen.nl/en/dd_index_en.php\">",
"       www.dnadiagnostieknijmegen.nl/en/dd_index_en.php",
"      </a>",
"     </li>",
"     <li>",
"      Laboratory of Molecular and Cell Biology, Instituto Dermopatico Dell'Immacolata, Rome, Italy (",
"      <a class=\"external\" href=\"mailto:d.castiglia@idi.it\">",
"       d.castiglia@idi.it",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stanford Dermatopathology Service:",
"      <a class=\"external\" href=\"file://dermatopathology.stanford.edu/services/epiderm.html\">",
"       dermatopathology.stanford.edu/services/epiderm.html",
"      </a>",
"      (for immunofluorescence mapping and electron microscopy)",
"     </li>",
"     <li>",
"      Australian EB Diagnostic Laboratory, Department of Anatomical Pathology, SEALS, St. George Hospital, Sydney (Dr D. Murrell):",
"      <a class=\"external\" href=\"file://www.blisters.org.au/AEBDL.html\">",
"       file://www.blisters.org.au/AEBDL.html",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061011\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four major types of epidermolysis bullosa (EB) are recognized on the basis of the ultrastructural level of skin cleavage: simplex (intraepidermal); junctional (intra-lamina lucida); dystrophic (sub-lamina densa); and Kindler syndrome (intraepidermal, intra-lamina lucida, and sub-lamina densa) (",
"      <a class=\"graphic graphic_figure graphicRef52111 \" href=\"mobipreview.htm?7/20/7493\">",
"       figure 1",
"      </a>",
"      ). Clinical, pathophysiological, and molecular criteria define more than 30 subtypes of EB (",
"      <a class=\"graphic graphic_table graphicRef77709 graphicRef67202 graphicRef55262 graphicRef81536 \" href=\"mobipreview.htm?27/19/27955\">",
"       table 1A-D",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=see_link\">",
"       \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      EB should be suspected in individuals with a history of recurrent blistering or erosions following mild trauma and in neonates presenting with blisters and erosions without other plausible etiology (eg, infection), especially if family history is positive for similar manifestations. &nbsp;(See",
"      <a class=\"local\" href=\"#H2394284\">",
"       'When to suspect EB'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1036886823\">",
"       'Other causes of blistering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin biopsy for immunofluorescence mapping (IFM) of a freshly induced blister is the first line approach for the diagnosis of EB. Identifying and contacting the laboratory before the biopsy is performed will ensure that the specimen is obtained and processed appropriately. Information on the centers for the diagnosis and treatment of EB is available from the website of the Dystrophic EB Research Association (DebRA)-International at",
"      <a class=\"external\" href=\"file://www.debra-international.org\">",
"       www.debra-international.org",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1211650349\">",
"       'Overview of approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IFM and transmission electron microscopy (TEM) allow the identification of the level of skin cleavage, morphologic alterations of epithelial adhesion structures in the basement membrane zone, and defective expression of specific protein components for identification of the subtype of EB. (See",
"      <a class=\"local\" href=\"#H2394305\">",
"       'Immunofluorescence microscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22232179\">",
"       'Transmission electron microscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutational analysis is not recommended as a first line diagnostic test for EB because of high cost and limited availability. However, mutational analysis may be necessary in patients with suspected Kindler syndrome, when the inheritance pattern is not clear, in families with a severely affected child, or when prenatal or preimplantation genetic diagnosis are planned. (See",
"      <a class=\"local\" href=\"#H2394326\">",
"       'Genetic diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1061030\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22232763\">",
"       'Preimplantation genetic diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H590744\">",
"       'Specialized laboratories for genetic diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/1\">",
"      Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.",
"     </a>",
"    </li>",
"    <li>",
"     Fine JD. Hereditary epidermolysis bullosa (EB) biopsy sites. file://www.beutnerlabs.com/request/biopsy-sites.php (Accessed on August 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/3\">",
"      Intong LR, Murrell DF. How to take skin biopsies for epidermolysis bullosa. Dermatol Clin 2010; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/4\">",
"      Michel B, Milner Y, David K. Preservation of tissue-fixed immunoglobulins in skin biopsies of patients with lupus erythematosus and bullous diseases--preliminary report. J Invest Dermatol 1972; 59:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/5\">",
"      Yiasemides E, Walton J, Marr P, et al. A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. Am J Dermatopathol 2006; 28:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/6\">",
"      Pohla-Gubo G, Cepeda-Valdes R, Hintner H. Immunofluorescence mapping for the diagnosis of epidermolysis bullosa. Dermatol Clin 2010; 28:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/7\">",
"      PEARSON RW. Studies on the pathogenesis of epidermolysis bullosa. J Invest Dermatol 1962; 39:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/8\">",
"      Eady RA, Dopping-Hepenstal PJ. Transmission electron microscopy for the diagnosis of epidermolysis bullosa. Dermatol Clin 2010; 28:211.",
"     </a>",
"    </li>",
"    <li>",
"     Fine JD, Smith LT. Nonmolecular diagnostic testing of inherited epidermolysis bullosa. In: Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry, Fine JD, Bauer EA, McGuire J, et al (Eds), The Johns Hopkins University Press, 1999. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/10\">",
"      Petronius D, Bergman R, Ben Izhak O, et al. A comparative study of immunohistochemistry and electron microscopy used in the diagnosis of epidermolysis bullosa. Am J Dermatopathol 2003; 25:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/11\">",
"      Pigors M, Kiritsi D, Kr&uuml;mpelmann S, et al. Lack of plakoglobin leads to lethal congenital epidermolysis bullosa: a novel clinico-genetic entity. Hum Mol Genet 2011; 20:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/12\">",
"      Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010; 130:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/13\">",
"      Castiglia D, Zambruno G. Molecular testing in epidermolysis bullosa. Dermatol Clin 2010; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/14\">",
"      Bolling MC, Lemmink HH, Jansen GH, Jonkman MF. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. Br J Dermatol 2011; 164:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/15\">",
"      Dang N, Murrell DF. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 2008; 17:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/16\">",
"      Has C. Molecular genetic assays for inherited epidermolysis bullosa. Clin Dermatol 2011; 29:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/17\">",
"      Lai-Cheong JE, McGrath JA. Kindler syndrome. Dermatol Clin 2010; 28:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/18\">",
"      Mallipeddi R, Bleck O, Mellerio JE, et al. Dilemmas in distinguishing between dominant and recessive forms of dystrophic epidermolysis bullosa. Br J Dermatol 2003; 149:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/19\">",
"      Fassihi H, McGrath JA. Prenatal diagnosis of epidermolysis bullosa. Dermatol Clin 2010; 28:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/20\">",
"      Pfendner EG, Nakano A, Pulkkinen L, et al. Prenatal diagnosis for epidermolysis bullosa: a study of 144 consecutive pregnancies at risk. Prenat Diagn 2003; 23:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39255/abstract/21\">",
"      Fassihi H, Liu L, Renwick PJ, et al. Development and successful clinical application of preimplantation genetic haplotyping for Herlitz junctional epidermolysis bullosa. Br J Dermatol 2010; 162:1330.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15452 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-630D6848AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39255=[""].join("\n");
var outline_f38_21_39255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1061011\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2394277\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2394284\">",
"      WHEN TO SUSPECT EB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1036886823\">",
"      Other causes of blistering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2394291\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211650349\">",
"      Overview of approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22232119\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2394298\">",
"      - Obtaining biopsies for EB diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2394305\">",
"      - Immunofluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22232179\">",
"      - Transmission electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2394319\">",
"      - Diagnostic accuracy of IFM and TEM analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2394326\">",
"      Genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4214194\">",
"      - Mutational analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4214201\">",
"      - Indications for mutational analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1061030\">",
"      - Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22232763\">",
"      - Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H590744\">",
"      - Specialized laboratories for genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1061011\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15452|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7493\" title=\"figure 1\">",
"      Basement membrane zone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15452|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/38/12897\" title=\"picture 1\">",
"      Incontinentia pigmenti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/27/15794\" title=\"picture 2\">",
"      Aplasia cutis congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/52/24386\" title=\"picture 3\">",
"      Focal dermal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/7/44145\" title=\"picture 4\">",
"      Bullous eruption in SM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/48/11010\" title=\"picture 5A\">",
"      Bullous impetigo infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/16/28933\" title=\"picture 5B\">",
"      Bullous impetigo pediatric",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/52/13121\" title=\"picture 5C\">",
"      Staphylococcal scalded skin syndrome - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/47/18161\" title=\"picture 6\">",
"      Sucking blister",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/16/43267\" title=\"picture 7A\">",
"      Chronic bullous disease of childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/3/32819\" title=\"picture 7B\">",
"      Chronic bullous disease of childhood 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/62/16359\" title=\"picture 8\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/29/15827\" title=\"picture 9\">",
"      Bullous pemphigoid in childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/36/22085\" title=\"picture 10\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/27/6581\" title=\"picture 11\">",
"      Inducing blister",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/16/6415\" title=\"table 1A\">",
"      EB simplex variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/28/9678\" title=\"table 1B\">",
"      JEB variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/9/21662\" title=\"table 1C\">",
"      DEB variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/53/15195\" title=\"table 1D\">",
"      Kindler syndrome 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/7/29819\" title=\"table 2\">",
"      EB-specific monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/56/1933\" title=\"table 3\">",
"      Antigenic alterations in EB skin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5801?source=related_link\">",
"      Congenital erythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28106?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3066?source=related_link\">",
"      Overview of the management of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39256="Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome";
var content_f38_21_39256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39256/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39256/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39256/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39256/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/21/39256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction from the atria to the ventricles normally occurs via the atrioventricular node (AV)-His-Purkinje system. Patients with a preexcitation syndrome have an additional or alternative pathway, known as an accessory pathway, which directly connects the atria and ventricle and bypasses the AV node. AV conduction through an accessory pathway (most commonly a direct AV connection) results in the earlier activation of the ventricles than if the impulse had traveled through the AV node; hence the term preexcitation.",
"   </p>",
"   <p>",
"    Accessory pathway is a generic term which may indicate either a \"tract\" which bypasses the AV node but inserts into the specialized conduction system (eg, the bundle of His, right or left bundles, or one of the fascicles), or a \"connection\" which bypasses the AV node and terminates directly within the myocardium. Other names that may be used include anomalous AV pathway, connection, or tract; accessory AV bypass pathway, connection, or tract; or simply AV bypass, tract, or pathway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13271?source=see_link\">",
"     \"General principles of asynchronous activation and preexcitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At other times, the specific sites of origin and termination are used. Examples include accessory atrioventricular connection, atrio-Hisian pathway or connection, or atriofascicular pathway or connection (",
"    <a class=\"graphic graphic_table graphicRef53343 \" href=\"mobipreview.htm?26/0/26635\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Preexcitation through an AV bypass tract, the bundle of Kent, produces the electrocardiographic pattern described by Wolff, Parkinson, and White in 1930 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/1\">",
"     1",
"    </a>",
"    ]. The terms preexcitation and Wolff-Parkinson-White (WPW) syndrome are often used interchangeably even though there are other forms of preexcitation. The electrocardiographic pattern of WPW should be differentiated from the \"WPW syndrome,\" since patients with the latter have both the electrocardiographic pattern of preexcitation and paroxysmal tachyarrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the anatomy and electrophysiologic properties of the accessory pathways. The related issue of asynchronous activation, the arrhythmias associated with WPW, and the pharmacologic and nonpharmacologic treatments of patients with this syndrome are discussed separately. (See appropriate topic reviews). A detailed discussion of electrophysiologic mapping techniques is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27305?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Use in specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several types of accessory pathways (",
"    <a class=\"graphic graphic_figure graphicRef69078 \" href=\"mobipreview.htm?23/5/23634\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53343 \" href=\"mobipreview.htm?26/0/26635\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic accessory pathway is the AV bypass tract or bundle of Kent in WPW that directly connects atrial and ventricular myocardium, bypassing the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system",
"     </li>",
"     <li>",
"      James fibers, atrionodal tracts, connect atrium to distal or compact AV node (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11272?source=see_link\">",
"       \"Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brechenmacher fibers (atrio-Hisian tracts) connect the atrium to His bundle",
"     </li>",
"     <li>",
"      Various types of Hisian-fascicular tracts, also known as Mahaim fibers, connect the atrium (atriofascicular pathways), AV node (nodofascicular pathways) or His bundle (fasciculoventricular) to distal Purkinje fibers or ventricular myocardium (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17943?source=see_link\">",
"       \"Mahaim fiber tachycardias\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The gross anatomy of AV accessory pathways should be considered in two planes that run transversely at the level of and parallel to the AV groove and longitudinally perpendicular to the AV groove [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transverse plane",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the transverse plane, bypass tracts can cross the AV groove anywhere except between the left and right fibrous trigones where the atrial myocardium is not in direct juxtaposition with ventricular myocardium. The remainder of the transverse plane can then be divided into quadrants consisting of the left free wall, posteroseptal, right free wall, and anteroseptal spaces (",
"    <a class=\"graphic graphic_figure graphicRef77941 \" href=\"mobipreview.htm?21/50/22319\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The distribution of accessory pathways within these regions is not homogeneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      46 to 60 percent of accessory pathways are found within the left free wall space",
"     </li>",
"     <li>",
"      25 percent are within the posteroseptal space",
"     </li>",
"     <li>",
"      13 to 21 percent of pathways are within the right free wall space",
"     </li>",
"     <li>",
"      2 percent are within the anteroseptal space",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The left and right free wall spaces can be subdivided into anterior, anterolateral, lateral, posterolateral, and posterior zones. Distinctive 12-lead ECG patterns of fully preexcited QRS morphology have been validated during surgical mapping and ablation of accessory pathways within each of these subdivisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/9-13\">",
"     9-13",
"    </a>",
"    ] Detailed knowledge of accessory pathway location within the free wall regions is of critical importance to the interventional electrophysiologist performing catheter ablation procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Longitudinal plane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory pathway anatomy in the longitudinal plane can be most easily understood by studying a longitudinal section of the left free wall region (",
"    <a class=\"graphic graphic_figure graphicRef76316 \" href=\"mobipreview.htm?3/12/3267\">",
"     figure 3",
"    </a>",
"    ). AV accessory pathways exist only between the annulus fibrosus and the epicardial reflection off the atrial and ventricular walls, confined within the AV groove subepicardial fat of the right and left free walls, the anteroseptal space, and the posteroseptal space. Accessory pathways insert directly into the atrial and basal ventricular myocardium, although they may course through the AV groove at a variable depth from subepicardial to subendocardial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also vascular structures located in these regions. These include the circumflex coronary artery and coronary sinus in the left free wall space; the coronary sinus, middle cardiac vein, and posterior descending artery in the posteroseptal space; and the right coronary artery in the anteroseptal and right free wall spaces.",
"   </p>",
"   <p>",
"    AV accessory pathways may run in an oblique course rather than perpendicular to the transverse plane of the AV groove. As a result, the fibers may have an atrial insertion point that is transversely several centimeters removed from the point of ventricular attachment. Finally, bypass tracts may occasionally exist as broad bands of tissue rather than discrete hair-like structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5306931\">",
"    <span class=\"h2\">",
"     Associated structural cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory pathways are associated with structural heart abnormalities. Patients with hypertrophic cardiomyopathy appear to have a higher incidence of accessory pathways than the normal population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome was mapped to a locus on chromosome 7q3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with Ebstein&rsquo;s anomaly can have right sided accessory pathways associated with the abnormal tricuspid valve and often have multiple accessory pathways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Posteroseptal accessory pathways may involve more than just the atrial and ventricular musculature, and include the musculature surrounding the coronary sinus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/16\">",
"     16",
"    </a>",
"    ]. In a study of 480 patients with posteroseptal or left posterior accessory pathways, 171 were found to involve the coronary sinus musculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/17\">",
"     17",
"    </a>",
"    ]. The delta wave was negative in lead II in 70 percent of these patients. A coronary sinus diverticulum was found in 21 percent of these patients at this tertiary referral center, but in only 2 percent of the patients who had not had a prior ablation attempt. For this reason, it is important to perform venography of the proximal coronary sinus during an ablation procedure in a patient with a posteroseptal accessory pathway when elimination of the pathway proves to be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGY OF PREEXCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal temporal and spatial sequence of atrial and ventricular activation is altered in the WPW type of preexcitation because conduction between the atria and ventricles involves both an accessory pathway and the normal AV node-His Purkinje system.",
"   </p>",
"   <p>",
"    The vast majority of accessory pathways generate a fast action potential due to the rapid inward sodium current, similar to normal His-Purkinje tissue and atrial and ventricular myocardium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .) As a result, they have constant antegrade and retrograde conduction at all rates until the refractory period is reached, at which time conduction is completely blocked (nondecremental conduction).",
"   </p>",
"   <p>",
"    In contrast, the AV node, which depends on the slow inward calcium current for generation and propagation of its action potential, exhibits decremental conduction in which the conduction time of the impulse propagating through the AV node increases as the cycle length shortens (heart rate increased) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, AV conduction is more rapid through the accessory pathway than through the AV node, a difference that is increased at fast heart rates.",
"   </p>",
"   <p>",
"    This difference has potentially great clinical importance. The progressive prolongation of AV nodal conduction time at faster atrial rates has a protective role, limiting the ventricular response to rapid atrial rates in atrial fibrillation or atrial flutter. This decreasing speed of conduction until some but not all beats are transmitted through the AV nodal tissue is called decremental conduction. Accessory pathways are dependent on the rapid inward sodium current for depolarization and characteristically do not demonstrate decremental conduction. As a result, arrhythmias that utilize accessory pathways can conduct rapidly leading to very fast ventricular rates that may degenerate into ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mahaim fibers may have somewhat different properties in that they may show slow and decremental anterograde conduction, proximal AV nodal-like electrophysiologic properties and distal bundle branch-like properties, conduction block in response to adenosine, and heat-induced automaticity during radiofrequency catheter ablation. Spontaneous automaticity may arise in Mahaim fibers, particularly during ablation procedures of the atrial insertion, and this may trigger antidromic circus movement tachycardias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ventricular activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since an AV accessory pathway bypasses and conducts faster than the AV node, the onset of ventricular activation is earlier than expected if depolarization occurred via the AV node. Since the accessory pathway exhibits nondecremental conduction, early activation remains constant at all heart rates.",
"   </p>",
"   <p>",
"    Preexcited intraventricular conduction in WPW spreads from the insertion point of the AV bypass tract in the ventricular myocardium via direct muscle fiber-to-muscle fiber conduction. This process is inherently slower than ventricular depolarization resulting from rapid His-Purkinje system conduction. Thus, the net effect is earlier initial excitation of the ventricles (via the accessory pathway) but slower activation of the ventricular myocardium than occurs normally.",
"   </p>",
"   <p>",
"    The net effect is that the QRS complex consists of fusion between early ventricular activation caused by preexcitation with the later ventricular activation resulting from transmission through the AV node and the infranodal conduction system to the ventricles. The initial part of ventricular activation is slowed and the upstroke of the QRS complex is slurred because of slow muscle fiber-to-muscle fiber conduction; this is termed a delta wave&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef73740 graphicRef53773 \" href=\"mobipreview.htm?15/14/15590\">",
"     figure 4A-B",
"    </a>",
"    ). The sooner conduction occurs over the accessory pathway in relation to the AV node, the greater the amount of myocardium depolarized via the accessory pathway, resulting in a more prominent or wider delta wave, and increasing prolongation of the QRS complex (",
"    <a class=\"graphic graphic_figure graphicRef62454 \" href=\"mobipreview.htm?2/55/2929\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Minimal preexcitation in WPW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preexcitation and delta waves may not be apparent in sinus rhythm in patients with WPW who have a left-lateral bypass tract as the antegrade route for conduction; in this setting, the time for the atrial impulse to reach the atrial insertion of the accessory pathway is longer than the time to reach the AV node. The presence of a septal Q wave in lead V6 of the surface electrocardiogram is useful to exclude minimal preexcitation with a high degree of reliability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/20\">",
"     20",
"    </a>",
"    ]. When there is uncertainty regarding the presence of ventricular preexcitation, vagal maneuvers can be performed or intravenous adenosine can be administered to cause transient AV nodal blockade.",
"   </p>",
"   <p>",
"    The P wave signal-averaged ECG may also be of help in identifying a concealed left-sided accessory pathway. In one series, such a bypass tract was associated with a more prolonged filtered P wave duration (119 versus 132 ms in controls or patients with an AV nodal reentrant tachycardia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10872?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, delta waves are not seen with non-WPW forms of preexcitation, such as Mahaim or James fibers, since these pathways terminate in the conducting system or in the ventricular myocardium close to the conducting system. Most Mahaim tachycardias, for example, are due to atriofascicular pathways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17943?source=see_link\">",
"     \"Mahaim fiber tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     PR interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the impulse bypasses the AV node, the preexcited PR interval is often shorter than what would be considered normal; however, it may not be abnormally short in the absolute sense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/22\">",
"     22",
"    </a>",
"    ]. The degree of PR interval shortening and the amount of QRS interval widening depend upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The balance between the antegrade conduction time and refractory period of the accessory pathway and those of the normal AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system; the conduction properties of both are variably influenced by the autonomic nervous system",
"     </li>",
"     <li>",
"      The atrial insertion point of the AV bypass tract",
"     </li>",
"     <li>",
"      The site of atrial impulse origin",
"     </li>",
"     <li>",
"      Interatrial conduction time",
"     </li>",
"     <li>",
"      Atrial refractoriness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these factors, preexcitation may be less apparent during sinus tachycardia when AV node conduction time is short due to elevated sympathetic tone and decreased vagal tone. In addition, as mentioned above, an AV bypass tract that crosses the AV groove in the left lateral region may result in inapparent preexcitation and minimal PR interval shortening in sinus rhythm because of the greater interatrial distance required for impulse propagation from the sinus node to the left atrial insertion of the bypass tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intermittent preexcitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent preexcitation should be distinguished from day-to-day variability in preexcitation which results from changes in AV nodal conduction in relation to those of the accessory pathway usually due to changes in autonomic tone. True intermittent preexcitation is characterized by abrupt loss of the delta wave, normalization of the QRS duration, and an increase in the PR interval during a continuous ECG recording in the absence of any significant change in heart rate. This finding is generally a reliable sign that the AV bypass tract has a relatively long antegrade refractory period and is not capable of frequent impulse conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preexcitation alternans",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preexcitation alternans, a QRS complex manifesting a delta wave alternates with a normal QRS complex. This is also a marker for an accessory pathway with a relatively long antegrade refractory period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Concertina effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of fusion of the QRS complex varies with the electrophysiologic properties of the accessory pathway, which are influenced by sympathetic and parasympathetic tone and their effect on the AV node. As a result, the appearance and width of the QRS complex depends upon the balance between preexcitation and normal excitation via the AV node. If AV nodal conduction is fast, the amount of myocardium activated via the accessory pathway is less, and hence there is a longer PR interval, less prominent delta wave, and narrower QRS complex. If AV nodal conduction is slow, more myocardium is activated via the accessory pathway, resulting in a shorter PR interval, more prominent delta wave, and wider QRS complex.",
"   </p>",
"   <p>",
"    Changing degrees of AV nodal conduction and hence fusion in some patients may cause the QRS duration and the PR interval to periodically wax and wane, resulting in an appearance referred to as the \"concertina effect\" of preexcitation (",
"    <a class=\"graphic graphic_waveform graphicRef53508 \" href=\"mobipreview.htm?32/21/33112\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef65293 \" href=\"mobipreview.htm?23/55/24447\">",
"     waveform 2",
"    </a>",
"    ). In this phenomenon, PR intervals and QRS complex durations show a cyclic pattern, eg, preexcitation becomes progressively more prominent over a number of QRS complex cycles followed by a gradual diminution in the degree of preexcitation over several QRS cycles despite a fairly constant heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Accessory pathways exhibiting decremental conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients have accessory pathways in which conduction slows at faster rates of stimulation (decremental conduction), similar to the situation with the AV node. As noted above, the progressive prolongation of AV nodal conduction time at faster atrial rates has a protective role, limiting the ventricular response to rapid atrial rates in atrial fibrillation or atrial flutter.",
"   </p>",
"   <p>",
"    Accessory pathways which display decremental conduction in one direction may exhibit varied electrophysiologic properties in the other. As an example, one study examined the characteristics of the accessory pathway in 74 patients with decremental accessory pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/25\">",
"     25",
"    </a>",
"    ]. Among 64 patients with retrograde decremental conduction, anterograde conduction was not present in 64 percent, was intermittent in 8 percent, and was nondecremental in 28 percent. Five patients had anterograde but not retrograde conduction, and five had conduction in both directions. Another study examined 384 symptomatic patients with a single AP and found that retrograde decremental conduction over the AP was present in the posteroseptal (17 percent), and left free wall (3 percent), but absent in the other locations. Anterograde decremental conduction was only seen in the right free wall location (12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Concealed accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although AV accessory pathways usually conduct antegradely and retrogradely, some AV bypass tracts are capable of propagating impulses in only one direction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/8,12,14,24,25,27\">",
"     8,12,14,24,25,27",
"    </a>",
"    ]. Bypass tracts that conduct only in an antegrade direction are uncommon. They often cross the right AV groove, and frequently possess decremental conduction properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/8,22,27-29\">",
"     8,22,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bypass tracts that conduct only in the retrograde direction occur more frequently with an incidence reported as high as 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/30\">",
"     30",
"    </a>",
"    ]. Because they do not preexcite the ventricles, the surface ECG during sinus rhythm appears normal and therefore these pathways are called \"concealed\". Some concealed pathways may be able to conduct anterograde, but have such long refractory periods that they do not conduct during sinus rhythm and are concealed. Preexcitation can sometimes be seen in patients with this type of a concealed accessory pathway after a long sinus pause, such as immediately after termination of AV reciprocating tachycardia. Most concealed AV bypass tracts exhibit nondecremental conduction and, because they serve as conduit for retrograde ventriculoatrial (VA) conduction, they are associated with reentrant arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. &nbsp;Concealed accessory pathways that have decremental properties are usually located in the posteroseptal region. However, these pathways also occur in nonseptal locations with an incidence as high as 25 percent in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H20061242#H20061242\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Prevalence of concealed accessory pathways'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RELATIONSHIP BETWEEN ACCESSORY PATHWAY SITE AND THE ELECTROCARDIOGRAPHIC PATTERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many articles have attempted to correlate the site of the accessory pathway with the ECG pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/13,33-37\">",
"     13,33-37",
"    </a>",
"    ]. However, the electrocardiographic appearance of activation depends upon the extent of preexcitation and fusion; as a result, the same pathway may not always produce the identical ECG pattern. Furthermore, as many as 13 percent of individuals with preexcitation have more than one accessory pathway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H8470594#H8470594\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Accessory pathway location'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surface ECG does, however, provide important clues for the cardiologist to direct invasive mapping. It also serves as a guide for the cardiologist or surgeon to anticipate the morbidity of the particular procedural approach required to treat a particular accessory pathway (eg, ablation of pathways near the AV node and bundle of His has a higher inherent risk of inducing AV block and requiring a permanent pacemaker).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Localizing the accessory AV connection site based upon the ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;A useful approach to map the location of the common form of accessory pathway, the accessory AV connection (AAVC), combines the algorithms of Milstein (",
"    <a class=\"graphic graphic_figure graphicRef77941 \" href=\"mobipreview.htm?21/50/22319\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef70648 \" href=\"mobipreview.htm?41/13/42205\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/13\">",
"     13",
"    </a>",
"    ] and Arruda (",
"    <a class=\"graphic graphic_figure graphicRef77941 \" href=\"mobipreview.htm?21/50/22319\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef57692 \" href=\"mobipreview.htm?12/56/13199\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. The Milstein approach accurately localizes the AAVC to general regions along the AV rings; the Arruda approach is more precise, as has been confirmed by endocardial mapping, and is helpful in further discriminating the septal areas of the AV rings. Distinctly classifying the",
"    <span class=\"nowrap\">",
"     posteroseptal/mid-septal/anteroseptal",
"    </span>",
"    areas also helps the clinician prepare the patient for different treatment options, including radiofrequency ablation, medical therapy, or monitoring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vector of the delta wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to assess the vector of the delta wave:",
"   </p>",
"   <p>",
"    Is the delta wave vector directed away from or isoelectric to the leftward leads I, aVL, or V6? In other words, is the delta wave a Q wave or isoelectric in I, aVL, or V6?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If yes and a left bundle branch block-type pattern is also present, (QRS &ge;0.09 sec in lead I with an rS pattern in V1 or V2), a right anteroseptal pathway is suggested (",
"      <a class=\"graphic graphic_waveform graphicRef50415 \" href=\"mobipreview.htm?28/47/29428\">",
"       waveform 3",
"      </a>",
"      ). This connection initiates a generally rightward activation of the right ventricle (RV) in one of the leftward leads (leading to negative delta waves in aVL",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      V6). The asynchronous activation of the right and then the left ventricle (LV) produces the LBBB-like ECG pattern. The QRS axis is greater than +30&ordm; which helps distinguish the right anteroseptal from a right lateral pathway.",
"     </li>",
"     <li>",
"      If yes and a LBBB-type configuration is not present, a left lateral pathway is suggested (",
"      <a class=\"graphic graphic_waveform graphicRef74370 \" href=\"mobipreview.htm?20/11/20670\">",
"       waveform 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef50322 \" href=\"mobipreview.htm?31/32/32270\">",
"       waveform 5",
"      </a>",
"      ). Preexcitation begins in the lateral portion of the left ventricle; as a result, initial activation is to the right as reflected by a negative delta wave in one or more of the leftward leads (ECG 2 shows isoelectric to negative polarity in I and aVL while ECG 3 shows a negative delta wave in aVL). The pattern may then resemble an atypical RBBB, because preexcitation begins in the left ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the delta waves in leads I, aVL and V6 are other than a Q wave or isoelectric, examine the vector first in the frontal plane and then in the horizontal plane. Specifically, see if the delta wave vector in the frontal plane forms a Q wave or is isoelectric in two of leads II, III, or aVR.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If yes, examine the horizontal plane. If there is an Rs or RS in V1, V2, or V3, a posteroseptal pathway is suggested (",
"      <a class=\"graphic graphic_waveform graphicRef69988 graphicRef57211 graphicRef59055 graphicRef71868 \" href=\"mobipreview.htm?29/58/30634\">",
"       waveform 6A-D",
"      </a>",
"      ). Preexcitation therefore begins in the posterior portion of the septum and sweeps anteriorly, giving the initial positive R complex in the anterior precordial leads. Further discrimination is discussed in the legends to the electrocardiograms.",
"     </li>",
"     <li>",
"      If yes, and the pattern is other than an Rs or RS in V1, V2, or V3, a right lateral pathway is suggested (",
"      <a class=\"graphic graphic_waveform graphicRef77218 \" href=\"mobipreview.htm?15/35/15920\">",
"       waveform 7",
"      </a>",
"      ). Preexcitation begins in the lateral portion of the right ventricle, which is anatomically anterior and to the right; as a result, activation is posteriorly and to the left. A LBBB-type pattern results because the RV is activated before the LV. The axis is less than +30&ordm; (ECG 5 has a negative delta wave in III and is isoelectric in aVF), which distinguishes the right lateral from the anteroseptal pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the pattern in leads II, III or aVF is not a Q or isoelectric delta wave, then:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A left bundle branch type of pattern (QRS equal to or greater than 90 msec in I and rS in V1 or V2) with a QRS axis of more than +30&ordm; suggests a right anteroseptal pathway (",
"      <a class=\"graphic graphic_waveform graphicRef50415 \" href=\"mobipreview.htm?28/47/29428\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A left bundle branch type of pattern (QRS equal to or greater than 90 msec in I and rS in V1 or V2) with an axis that is +30&ordm; or less suggests a right",
"      <strong>",
"      </strong>",
"      lateral pathway (",
"      <a class=\"graphic graphic_waveform graphicRef77218 \" href=\"mobipreview.htm?15/35/15920\">",
"       waveform 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An Rs or RS in V1 or V2, but a pattern not that of a left bundle branch type as defined above, suggests a left lateral pathway (",
"      <a class=\"graphic graphic_waveform graphicRef74370 \" href=\"mobipreview.htm?20/11/20670\">",
"       waveform 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef50322 \" href=\"mobipreview.htm?31/32/32270\">",
"       waveform 5",
"      </a>",
"      ). If other than an Rs or RS, the pathway may be difficult to localize and probably represents a left anterior lateral pathway (",
"      <a class=\"graphic graphic_waveform graphicRef69928 \" href=\"mobipreview.htm?15/24/15759\">",
"       waveform 8",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recently, a new complicated algorithm has been proposed based upon a stepwise discriminant analysis of 18 variables in patients who had undergone successful catheter ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right-sided pathways were distinguished from left-sided pathways by the QRS transition in V1 to V3.",
"     </li>",
"     <li>",
"      Anterior-posterior, septal, and lateral pathways were localized by an analysis of delta wave and QRS polarities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The algorithm was quite successful in identifying right- and left-sided accessory pathways, right free wall from right septal, right anterolateral from posterolateral, and anteroseptal from other right septal pathways (",
"    <a class=\"graphic graphic_waveform graphicRef51236 \" href=\"mobipreview.htm?13/17/13584\">",
"     waveform 9",
"    </a>",
"    ). Left anterolateral pathways were also distinguished from left posterior pathways, and right posterolateral pathways were distinguished from left posteroseptal pathways.",
"   </p>",
"   <p>",
"    The reader who wishes to pursue the electrocardiographic patterns further should consult the sophisticated and complex scheme based upon delta wave polarity proposed by Gallagher and his colleagues and the summary table [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mahaim fibers may be suggested by a narrow QRS with an rS pattern in lead III. During tachycardia, these individuals usually have a LBBB-like QRS complex with left axis deviation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/38\">",
"     38",
"    </a>",
"    ]. A more detailed discussion for the specialist can be found in the article by Sternick and Gerkin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39256/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H187776717\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a preexcitation syndrome have an additional or alternative pathway, known as an accessory pathway, which directly connects the atria and ventricle and bypasses the AV node. AV conduction through an accessory pathway (most commonly a direct AV connection) results in the earlier activation of the ventricles than if the impulse had traveled through the AV node. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some accessory pathways are associated with structural heart abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic accessory pathway is the atrioventricular (AV) bypass tract or bundle of Kent in WPW that directly connects atrial and ventricular myocardium, bypassing the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delta waves may not be apparent in sinus rhythm in patients with WPW who have a left-lateral bypass tract as the antegrade route for conduction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Minimal preexcitation in WPW'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although AV accessory pathways usually conduct antegrade and retrograde, some AV bypass tracts are capable of propagating impulses in only one direction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Concealed accessory pathways'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The electrocardiographic appearance of activation depends upon the extent of preexcitation and fusion; as a result, the same pathway may not always produce the identical ECG pattern. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Relationship between accessory pathway site and the electrocardiographic pattern'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/1\">",
"      Wolff L, Parkinson J, White PD. Bundle branch block with a short P-R interval in healthy young people prone to paroxysmal tachycardia. Am Heart J 1930; 5:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/2\">",
"      Definition of terms related to cardiac rhythm. Am Heart J 1978; 95:796.",
"     </a>",
"    </li>",
"    <li>",
"     Waller BF. Clinicopathological correlations of the human cardiac conduction system. In: Cardiac Electrophysiology, Zipes DP, Jalife J (Eds), WB Saunders, Philadelphia 1990. p.249.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/4\">",
"      Anderson RH, Becker AE, Brechenmacher C, et al. Ventricular preexcitation. A proposed nomenclature for its substrates. Eur J Cardiol 1975; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     Ferguson TB, Cox JL. Surgical treatment for the Wolff-Parkinson-White syndrome: the endocardial approach. In: Cardiac Electrophysiology, Zipes DP, Jalife J (Eds), WB Saunders, Philadelphia 1990. p.897.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/6\">",
"      Cox JL, Gallagher JJ, Cain ME. Experience with 118 consecutive patients undergoing operation for the Wolff-Parkinson-White syndrome. J Thorac Cardiovasc Surg 1985; 90:490.",
"     </a>",
"    </li>",
"    <li>",
"     Cain ME, Cox JL. Surgical treatment of supraventricular arrhythmias. In: Management of cardiac arrhythmias: the nonpharmacologic approach, Platia E (Ed), JB Lippincott, Philadelphia 1987. p.304.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/8\">",
"      Gallagher JJ, Sealy WC, Kasell J. Intraoperative mapping studies in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1979; 2:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/9\">",
"      Gallagher JJ, Pritchett EL, Sealy WC, et al. The preexcitation syndromes. Prog Cardiovasc Dis 1978; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/10\">",
"      Reddy GV, Schamroth L. The localization of bypass tracts in the Wolff-Parkinson-White syndrome from the surface electrocardiogram. Am Heart J 1987; 113:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/11\">",
"      Fananapazir L, German LD, Gallagher JJ, et al. Importance of preexcited QRS morphology during induced atrial fibrillation to the diagnosis and localization of multiple accessory pathways. Circulation 1990; 81:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/12\">",
"      Lindsay BD, Crossen KJ, Cain ME. Concordance of distinguishing electrocardiographic features during sinus rhythm with the location of accessory pathways in the Wolff-Parkinson-White syndrome. Am J Cardiol 1987; 59:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/13\">",
"      Milstein S, Sharma AD, Guiraudon GM, Klein GJ. An algorithm for the electrocardiographic localization of accessory pathways in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1987; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/14\">",
"      Cain ME, Luke RA, Lindsay BD. Diagnosis and localization of accessory pathways. Pacing Clin Electrophysiol 1992; 15:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/15\">",
"      MacRae CA, Ghaisas N, Kass S, et al. Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995; 96:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/16\">",
"      Chauvin M, Shah DC, Ha&iuml;ssaguerre M, et al. The anatomic basis of connections between the coronary sinus musculature and the left atrium in humans. Circulation 2000; 101:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/17\">",
"      Sun Y, Arruda M, Otomo K, et al. Coronary sinus-ventricular accessory connections producing posteroseptal and left posterior accessory pathways: incidence and electrophysiological identification. Circulation 2002; 106:1362.",
"     </a>",
"    </li>",
"    <li>",
"     Prystowsky EN, Page RL. Electrophysiology and autonomic influences of the human atrioventricular node. In: Electrophysiology of the Sinoatrial and Atrioventricular Nodes, Mazgalev T, Dreifus L, Michelson EL (Eds).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/19\">",
"      Sternick EB, Timmermans C, Sosa E, et al. The electrocardiogram during sinus rhythm and tachycardia in patients with Mahaim fibers: the importance of an \"rS\" pattern in lead III. J Am Coll Cardiol 2004; 44:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/20\">",
"      Bogun F, Kalusche D, Li YG, et al. Septal Q waves in surface electrocardiographic lead V6 exclude minimal ventricular preexcitation. Am J Cardiol 1999; 84:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/21\">",
"      Yoshida T, Ikeda H, Hiraki T, et al. Detection of concealed left sided accessory atrioventricular pathway by P wave signal averaged electrocardiogram. J Am Coll Cardiol 1999; 33:55.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Preexcitation Syndromes. In: Clinical Cardiac Electrophysiology, Lea &amp; Febiger, Philadelphia 1993. p.311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/23\">",
"      German LD, Gallagher JJ. Functional properties of accessory atrioventricular pathways in Wolff-Parkinson-White syndrome. Clinical implications. Am J Med 1984; 76:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/24\">",
"      Nalos PC, Deng Z, Gang ES, et al. Intermittent preexcitation: Clinical recognition and management. Pract Cardiol 1985; 11:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/25\">",
"      Chen SA, Tai CT, Chiang CE, et al. Electrophysiologic characteristics, electropharmacologic responses and radiofrequency ablation in patients with decremental accessory pathway. J Am Coll Cardiol 1996; 28:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/26\">",
"      de Chillou C, Rodriguez LM, Schl&auml;pfer J, et al. Clinical characteristics and electrophysiologic properties of atrioventricular accessory pathways: importance of the accessory pathway location. J Am Coll Cardiol 1992; 20:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/27\">",
"      Murdock CJ, Leitch JW, Teo WS, et al. Characteristics of accessory pathways exhibiting decremental conduction. Am J Cardiol 1991; 67:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/28\">",
"      Tchou P, Lehmann MH, Jazayeri M, Akhtar M. Atriofascicular connection or a nodoventricular Mahaim fiber? Electrophysiologic elucidation of the pathway and associated reentrant circuit. Circulation 1988; 77:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/29\">",
"      Gillette PC, Garson A Jr, Cooley DA, McNamara DG. Prolonged and decremental antegrade conduction properties in right anterior accessory connections: Wide QRS antidromic tachycardia of left bundle branch block pattern without Wolff-Parkinson-White configuration in sinus rhythm. Am Heart J 1982; 103:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/30\">",
"      Ross DL, Uther JB. Diagnosis of concealed accessory pathways in supraventricular tachycardia. Pacing Clin Electrophysiol 1984; 7:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/31\">",
"      Gillette PC. Concealed anomalous cardiac conduction pathways: a frequent cause of supraventricular tachycardia. Am J Cardiol 1977; 40:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/32\">",
"      Meiltz A, Weber R, Halimi F, et al. Permanent form of junctional reciprocating tachycardia in adults: peculiar features and results of radiofrequency catheter ablation. Europace 2006; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/33\">",
"      Fitzpatrick AP, Gonzales RP, Lesh MD, et al. New algorithm for the localization of accessory atrioventricular connections using a baseline electrocardiogram. J Am Coll Cardiol 1994; 23:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/34\">",
"      Gallagher JJ, Sealy WC, Kasell J, Wallace AG. Multiple accessory pathways in patients with the pre-excitation syndrome. Circulation 1976; 54:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/35\">",
"      Arruda M, Wang X, McClennand J, et al. ECG algorithm for predicting sites of successful radiofrequency ablation of accessory pathways (abstract). Pacing Clin Electrophysiol 1993; 16(Pt 2):865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/36\">",
"      Epstein AE, Kirklin JK, Holman WL, et al. Intermediate septal accessory pathways: electrocardiographic characteristics, electrophysiologic observations and their surgical implications. J Am Coll Cardiol 1991; 17:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/37\">",
"      Arruda MS, McClelland JH, Wang X, et al. Development and validation of an ECG algorithm for identifying accessory pathway ablation site in Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 1998; 9:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/38\">",
"      Sternick EB, Sosa EA, Timmermans C, et al. Automaticity in Mahaim fibers. J Cardiovasc Electrophysiol 2004; 15:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39256/abstract/39\">",
"      Sternick EB, Gerken LM. The 12-lead ECG in patients with Mahaim fibers. Ann Noninvasive Electrocardiol 2006; 11:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 953 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39256=[""].join("\n");
var outline_f38_21_39256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H187776717\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transverse plane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Longitudinal plane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5306931\">",
"      Associated structural cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ELECTROPHYSIOLOGY OF PREEXCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ventricular activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Minimal preexcitation in WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PR interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intermittent preexcitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preexcitation alternans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Concertina effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Accessory pathways exhibiting decremental conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Concealed accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RELATIONSHIP BETWEEN ACCESSORY PATHWAY SITE AND THE ELECTROCARDIOGRAPHIC PATTERN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Localizing the accessory AV connection site based upon the ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vector of the delta wave",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H187776717\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/953|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/13/42205\" title=\"algorithm 1\">",
"      Milstein mapping algorithm localize accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/56/13199\" title=\"algorithm 2\">",
"      Arruda mapping algorithm localize accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/953|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/5/23634\" title=\"figure 1\">",
"      Anatomy AV accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/50/22319\" title=\"figure 2\">",
"      Schematic anatomic locations accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/12/3267\" title=\"figure 3\">",
"      Schematic LV free wall accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/58/929\" title=\"figure 4A\">",
"      Accessory AV pathways I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/19/2353\" title=\"figure 4B\">",
"      Accessory AV pathways II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/55/2929\" title=\"figure 5\">",
"      Accessory AV pathways III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/953|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/0/26635\" title=\"table 1\">",
"      Terminology of preexcitation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/953|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?32/21/33112\" title=\"waveform 1\">",
"      12-lead ECG WPW concertina effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?23/55/24447\" title=\"waveform 2\">",
"      ECG strip WPW concertina effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/47/29428\" title=\"waveform 3\">",
"      12-lead ECG right anterior septal WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?20/11/20670\" title=\"waveform 4\">",
"      12-lead ECG left lateral WPW I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/32/32270\" title=\"waveform 5\">",
"      12-lead ECG left lateral WPW II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?18/48/19200\" title=\"waveform 6A\">",
"      12-lead ECG right posteroseptal WPW I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?15/42/16037\" title=\"waveform 6B\">",
"      12-lead ECG right posteroseptal WPW II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?36/31/37364\" title=\"waveform 6C\">",
"      12-lead ECG right posteroseptal WPW III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?13/59/14271\" title=\"waveform 6D\">",
"      12-lead ECG left posteroseptal WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?15/35/15920\" title=\"waveform 7\">",
"      12-lead ECG right lateral WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?15/24/15759\" title=\"waveform 8\">",
"      12-lead ECG left anterior lateral WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?13/17/13584\" title=\"waveform 9\">",
"      12-lead ECG midseptal WPW",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27305?source=related_link\">",
"      Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13271?source=related_link\">",
"      General principles of asynchronous activation and preexcitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11272?source=related_link\">",
"      Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17943?source=related_link\">",
"      Mahaim fiber tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39257="Epidemiology and clinical manifestations of adenovirus infection";
var content_f38_21_39257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of adenovirus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Phyllis Flomenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/21/39257/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/21/39257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are a family of viruses that are an important cause of febrile illnesses in young children. They are most frequently associated with upper respiratory tract syndromes such as pharyngitis or coryza, but can also cause pneumonia. Less commonly, adenoviruses cause gastrointestinal, ophthalmologic, genitourinary, and neurologic diseases. Most adenoviral diseases are self-limiting, although fatal infections can occur in immunocompromised hosts and occasionally in healthy children and adults.",
"   </p>",
"   <p>",
"    In addition to their importance as infectious agents, adenoviruses are being studied intensively as vectors to deliver foreign genes both for gene therapy and for immunization against tumors and certain infections, such as HIV-1 and malaria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/52/26441?source=see_link\">",
"     \"Adenovirus pathogenesis and vector applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology and clinical manifestations of adenovirus infections will be reviewed here. Issues relating to pathogenesis, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=see_link\">",
"     \"Diagnosis and treatment of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIRION STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses have a double-stranded DNA genome of approximately 35 kb surrounded by a nonenveloped icosahedron with fiber-like projections from each of the 12 vertices. The fiber protein is attached noncovalently to the icosahedron by a pentameric polypeptide named penton base. The fiber protein from most adenoviruses, except subgroup B, binds to the cellular receptor CAR (coxsackie-adenovirus receptor), which also binds coxsackie B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/1\">",
"     1",
"    </a>",
"    ]. Group B adenoviruses have been shown to bind to CD46, a complement related protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The penton base mediates internalization via interaction with specific cellular integrins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major surface protein of the virion is the trimeric polypeptide hexon. Group-reactive antigenic determinants are present on the hexon proteins from all human adenoviruses. Type-specific neutralizing epitopes are present both on the fiber and hexon proteins with minor sites on the penton base. In addition, many adenoviruses hemagglutinate rat or rhesus red blood cells; this property is related to the fiber protein.",
"   </p>",
"   <p>",
"    Most adenoviruses readily infect human epithelial cell lines, exhibiting a characteristic cytopathic effect. This property is often used to isolate adenoviruses from clinical specimens in diagnostic virology laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses have a worldwide distribution and infections occur throughout the year. Adenoviruses cause 5 to 10 percent of all febrile illnesses in infants and young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/5\">",
"     5",
"    </a>",
"    ]. Most individuals have serologic evidence of prior adenoviral infection by the age of 10.",
"   </p>",
"   <p>",
"    Adenovirus infections are prevalent in daycare centers and in households with young children. Nosocomial transmission also has been documented.",
"   </p>",
"   <p>",
"    Many epidemics of adenoviral disease have been described, including pharyngoconjunctival fever in summer camps and in association with public swimming pools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/6\">",
"     6",
"    </a>",
"    ], keratoconjunctivitis in medical facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/7\">",
"     7",
"    </a>",
"    ], and serious acute respiratory disease in military recruits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Military recruits'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of adenovirus can occur via aerosol droplets, the fecal-oral route, and by contact with contaminated fomites. Adenoviruses can survive for long periods on environmental surfaces; they are resistant to lipid disinfectants because they are nonenveloped, but are inactivated by heat, formaldehyde, or bleach (sodium hypochlorite).",
"   </p>",
"   <p>",
"    There are several other modes of adenovirus transmission:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates can acquire adenoviral infection from exposure to cervical secretions at birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. The presence of adenovirus has been documented in cervical cells from the mother of a neonate who died from adenoviral pneumonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serologic evidence that adenoviruses can be transmitted from donor kidney and liver transplants suggests that these organs occasionally harbor adenoviruses in a latent form [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serotype prevalence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 50 human adenovirus serotypes have been identified based upon antigenic determinants detected by viral neutralization assay. Serotypes are further classified into six subgroups, A to F, based upon differences in patterns of hemagglutination. Serotypes within each subgroup are closely related at the DNA level and frequently share similar biologic properties. As examples, subgroup B types 11, 34, and 35 cause hemorrhagic cystitis, whereas subgroup D types 8, 19, and 37 are associated with keratoconjunctivitis (",
"    <a class=\"graphic graphic_table graphicRef63104 \" href=\"mobipreview.htm?34/24/35211\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prevalence of the different serotypes cannot be determined with confidence since the vast majority of patients with adenovirus infection are not cultured. This issue was addressed in a study in which 1653 clinical adenovirus isolates were collected from 22 hospital laboratories between 2004 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/14\">",
"     14",
"    </a>",
"    ]. The following distribution was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serotype 3 (subgroup B) &mdash; 35 percent",
"     </li>",
"     <li>",
"      Serotype 2 (subgroup C) &mdash; 24 percent",
"     </li>",
"     <li>",
"      Serotype 1 (subgroup C) &mdash; 18 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These serotypes are primarily associated with upper respiratory tract diseases (",
"    <a class=\"graphic graphic_table graphicRef63104 \" href=\"mobipreview.htm?34/24/35211\">",
"     table 1",
"    </a>",
"    ). However, the distribution of adenovirus serotypes is different in military recruits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Military recruits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning in 1971, military recruits in the United States received a highly effective, enteric-coated, oral live vaccine with adenovirus types 4 (subgroup E) and 7 (subgroup B); manufacture of this vaccine was discontinued in 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/15\">",
"     15",
"    </a>",
"    ]. Since that time, both susceptibility and clinical infection due to adenovirus have increased in military recruits. Rare fatalities have been reported in recruits due to probable adenovirus pneumonia with or without accompanying encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 341 military recruits in 2004 found that more than three-quarters were susceptible to either adenovirus type 4 or type 7 infection and, during active surveillance, one-quarter developed a febrile respiratory illness attributable to adenovirus serotype 4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/16\">",
"       16",
"      </a>",
"      ]. Furthermore, the percentage of recruits seropositive for this strain increased from 34 percent at enrollment to 97 percent by the end of the study. Potential sources of transmission included environmental contamination and extended pharyngeal shedding of virus.",
"     </li>",
"     <li>",
"      Among 584 clinical adenovirus isolates from military recruits collected between 2004 and 2006, 93 percent were serotype 4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/14\">",
"       14",
"      </a>",
"      ]. However, the distribution appears to be changing. In a series of 1867 military recruits with adenovirus respiratory infections, serotype 4 was the most prevalent serotype between 2002 and 2005 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/17\">",
"       17",
"      </a>",
"      ], while in 2006, subgroup B adenoviruses became more prevalent, including types 3, 7, 21, and 14. The emergence of adenovirus 14 is discussed in detail below. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adenovirus 14'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increasing prevalence of adenovirus infection in military recruits has raised interest in reinstituting the vaccine program in the military [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ]. In 2011, a new live, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9524?source=see_link\">",
"     adenovirus vaccine",
"    </a>",
"    against adenovirus serotypes 4 and 7 was approved for use in United States military personnel aged 17 through 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adenovirus 14",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenovirus 14 is a subgroup B serotype that was first identified in military recruits in the Netherlands in 1955. Since then, it has caused sporadic outbreaks in civilians and military recruits throughout Europe during the 1950s and 1960s. It emerged in 2005 in the United States, and has caused several outbreaks of pneumonia in both military recruits and civilians.",
"   </p>",
"   <p>",
"    Adenovirus 14 was detected in the United States in 2006 when it was associated with a fatal respiratory illness in a 12 day old infant in New York [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21\">",
"     21",
"    </a>",
"    ]. Clusters of severe acute adenovirus 14 respiratory disease have been subsequently identified in Oregon, Washington, Texas, and Alaska [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In a report that included 140 patients, 38 percent were hospitalized, 17 percent were admitted to intensive care units, and 5 percent died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21\">",
"     21",
"    </a>",
"    ]. In a retrospective review published subsequently, it was shown that adenovirus 14 had emerged in Oregon in 2005 and became the prevalent serotype in 2006 and 2007, causing over 50 percent of adenovirus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cluster in Texas involved military recruits at an Air Force base [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/25\">",
"     25",
"    </a>",
"    ]. Preexisting antibodies against adenovirus 7 were detected in 7 of 19 individuals with mild illness, but in none of 16 individuals with pneumonia caused by adenovirus 14, suggesting that adenovirus 7-specific antibodies might provide some degree of cross-protection against adenovirus 14. Among military recruits in Texas hospitalized with pneumonia during the outbreak, adenovirus 14 was not associated with excess morbidity or mortality compared with other causes of pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/26\">",
"     26",
"    </a>",
"    ]. However, women with adenovirus 14 infection had higher rates of hospitalization than men (83 versus 40 percent).",
"   </p>",
"   <p>",
"    Adenovirus 14 has also been identified in military recruits at a number of other bases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/17,27\">",
"     17,27",
"    </a>",
"    ], in health care workers (HCW) and a household contact of a HCW [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], and in two children and an adult in California with severe pneumonia superimposed upon chronic pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/30\">",
"     30",
"    </a>",
"    ]. It also caused an outbreak of pneumonia among a group of individuals who socialized and smoked together in Alaska [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/23\">",
"     23",
"    </a>",
"    ]. A study of healthcare personnel at a military hospital where 15 trainees were hospitalized with pneumonia caused by adenovirus 14 suggested likely nosocomial transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of 99 isolates from military and civilian cases of adenovirus 14 infection in the United States showed that all isolates were identical and suggested that they arose from recombination among adenovirus 11 and adenovirus 14 ancestral strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of adenoviral disease vary according to the age and immunocompetence of the host (",
"    <a class=\"graphic graphic_table graphicRef75951 \" href=\"mobipreview.htm?25/27/26043\">",
"     table 2",
"    </a>",
"    ). Severe disease has been associated with type 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/32-36\">",
"     32-36",
"    </a>",
"    ], type 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/14\">",
"     14",
"    </a>",
"    ], type 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/14,37\">",
"     14,37",
"    </a>",
"    ], and, more recently as noted in the previous section, type 14 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21,30\">",
"     21,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenoviruses can cause persistent infections, with the virus being shed in the feces for months to years after acute infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are the most common viruses isolated from young children with febrile respiratory illnesses. The usual duration of illness is five to seven days although symptoms may persist for up to two weeks. Bacterial superinfections can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pharyngitis and coryza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngitis and coryza are common presentations of adenovirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Pharyngitis is frequently associated with conjunctivitis, laryngotracheitis, bronchitis, or pneumonia. Fever and other systemic manifestations such as malaise, headache, myalgia, and abdominal pain are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/40\">",
"     40",
"    </a>",
"    ]. In many cases, exudative tonsillitis and cervical adenopathy may be present, a syndrome which can be clinically indistinguishable from group A streptococcal infection. Adenoviruses are the most common cause of tonsillitis in young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Otitis media and less common presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media is another common presentation, especially in children under age one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, the presence of adenovirus in middle ear fluid has only been documented in a few cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/41\">",
"     41",
"    </a>",
"    ]. Less frequently, adenoviruses cause a pertussis-like syndrome, bronchiolitis, coryza without fever, or an exanthem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are responsible for approximately 10 percent of pneumonias in children. A number of adenovirus serotypes (1, 2, 3, 4, 5, 7, 14, 21, and 35) have been reported to cause pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21,30,42,43\">",
"     21,30,42,43",
"    </a>",
"    ]. Subgroup B types 3, 7, 14, and 21 have been associated with severe and complicated pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21,30,44-47\">",
"     21,30,44-47",
"    </a>",
"    ]. Pneumonia is more severe in infants than older children, and may be associated with lethargy, diarrhea, and vomiting. Extrapulmonary complications occasionally occur, including meningoencephalitis, hepatitis, myocarditis, nephritis, neutropenia, and disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiography in adenoviral pneumonia reveals diffuse bilateral pulmonary infiltrates similar to those of other viral pneumonias. Pathologic changes include necrotizing bronchitis, bronchiolitis, and pneumonia with mononuclear cell infiltration, hyaline membranes, and necrosis.",
"   </p>",
"   <p>",
"    There is a high incidence of pulmonary sequelae in children, especially bronchiectasis. Neonates and infants with underlying diseases are at high risk for fatal adenoviral pneumonia. On the other hand, pneumococcal vaccination has been associated with a reduction in the incidence of pneumonia in infants with adenovirus and other respiratory virus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/50\">",
"     50",
"    </a>",
"    ]. This observation suggests that the pneumococcus is an important pathogen in virus-associated pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H10#H10\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acute respiratory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young adults, a syndrome of acute respiratory disease can occur under the special conditions of fatigue and crowding present in military training camps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/8\">",
"     8",
"    </a>",
"    ]. Symptoms include fever, pharyngitis, cough, hoarseness, and conjunctivitis. Other acute respiratory complications include pneumonia and, in young children, bronchiolitis obliterans and bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21,30,37,51,52\">",
"     21,30,37,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngoconjunctival fever is a classic adenoviral syndrome that consists of a benign follicular conjunctivitis often accompanied by a febrile pharyngitis and cervical adenitis. Outbreaks of pharyngoconjunctival fever have been described, especially in summer camps in association with swimming pools or lakes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/6\">",
"     6",
"    </a>",
"    ]. Adenovirus subgroup B types 3 and 7 are the most common isolates, but multiple serotypes from subgroups B, C, D, and E have been implicated.",
"   </p>",
"   <p>",
"    Epidemic keratoconjunctivitis (EKC) is a more serious disease associated primarily with the subgroup D types 8, 19, and 37. It is characterized by bilateral conjunctivitis with preauricular adenopathy, followed by the development of painful corneal opacities. Although the disease is self-limited and virtually never results in permanent corneal damage, it can run a protracted course lasting up to four weeks. It causes severe pain and blurry vision and incurs significant economic losses in the workplace.",
"   </p>",
"   <p>",
"    EKC may be transmitted in medical offices by the ophthalmologist's hands and contaminated instruments or eye drops. In one report of EKC due to adenovirus type 8 in a neonatal intensive care unit, where premature infants underwent repetitive eye exams, the outbreak spread from neonates to the staff and then to their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/7\">",
"     7",
"    </a>",
"    ]. In another review of an adenovirus type 8 epidemic, the authors demonstrated that almost 50 percent of patients diagnosed with EKC carried virus on their hands, and that the virus remained viable on inanimate surfaces for up to 35 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children, 5 to 10 percent of acute diarrheal illnesses are caused by the subgroup F adenoviruses types 40 and 41. These enteric adenoviruses were first identified in stool specimens by electron microscopy and require special cell lines for growth. Specific adenovirus antigen assays or polymerase chain reaction assays can be used for detection of these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and treatment of adenovirus infection\", section on 'Diarrhea in young children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of over 400 cases of acute infantile gastroenteritis, enteric adenoviruses were the sole recognizable cause of diarrhea in 7.2 percent of cases; no isolates were found among 200 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/54\">",
"     54",
"    </a>",
"    ]. Diarrhea was prolonged, lasting from 8 to 12 days. A review of another outbreak in several day care centers found that 38 percent of 249 young children had positive stool specimens, although only one-half were symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enteric adenoviruses also may be a cause of nosocomial infection, as suggested by one report of 14 cases of enteric adenovirus-related diarrhea in hospitalized infants over a three month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike types 40 and 41, epidemiologic studies have not shown a clear correlation between most other serotypes and gastroenteritis. However, the subgroup A type 31 has been associated with infantile diarrhea in some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, lower serotype adenoviruses have been associated with mesenteric adenitis, which may mimic appendicitis and occasionally cause intussusception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenoviruses may be excreted in feces for months after a primary infection. Thus, a positive stool culture for adenovirus is not usually clinically significant as a cause of diarrhea.",
"   </p>",
"   <p>",
"    In immunocompromised hosts, symptomatic gastroenteritis has been associated with a range of adenovirus serotypes. Additionally, hepatitis is a well-described complication of adenovirus infections in immunocompromised hosts, especially with subgroup C type 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/59\">",
"     59",
"    </a>",
"    ]. Adenovirus hepatitis is a particular problem in pediatric liver transplant recipients and may be fatal in these individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genitourinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenovirus subgroup B types 11 and 21 have been associated with acute hemorrhagic cystitis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/60\">",
"     60",
"    </a>",
"    ]. This self-limited disease is more common in males and is usually not accompanied by fever or hypertension. Its significance lies in the potential confusion with other, more serious diseases of the kidney such as glomerulonephritis.",
"   </p>",
"   <p>",
"    In adults, adenovirus subgroup D types 19 and 37 have been occasionally associated with urethritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In immunocompromised patients, adenovirus subgroup B types 11, 34, and 35 can cause hemorrhagic cystitis and tubulointerstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis and encephalitis have been reported occasionally in association with adenovirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/65\">",
"     65",
"    </a>",
"    ]. Neurologic involvement may be a primary manifestation or found in association with severe pneumonia, especially when infection is due to subgroup B type 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Disseminated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated adenovirus infection has been reported in both immunocompromised and immunocompetent children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/66\">",
"     66",
"    </a>",
"    ] and in adults who have undergone hematopoietic cell or solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/67\">",
"     67",
"    </a>",
"    ]. In a retrospective review of children with adenovirus infection, 2.5 percent (11 of 440) had disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/66\">",
"     66",
"    </a>",
"    ]. Of these, 54 percent (6 of 11) were immunocompromised. Mortality from disseminated disease was 73 percent overall (83 percent among immunocompromised and 60 percent among immunocompetent hosts).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two series of acute myocarditis in children, adenovirus was the most common cause of viral myocarditis, occurring in 60 percent of PCR-proven cases of viral myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Adenovirus has occasionally been associated with viral myositis accompanied by rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=see_link\">",
"     \"Viral myositis\"",
"    </a>",
"    .) Fewer than 10 cases of adenovirus-associated arthritis have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     INFECTIONS IN IMMUNOCOMPROMISED HOSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of clinical syndromes can occur in immunocompromised individuals with adenovirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/74\">",
"     74",
"    </a>",
"    ]. Reactivation of endogenous virus plays a role in adenoviral diseases in these patients. The major reservoirs for persistent adenovirus infections and the mechanisms of viral persistence are unknown; however, CD4 lymphocytes found in tonsils can harbor adenoviruses for a prolonged period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of adenovirus infection can range from asymptomatic shedding to fatal disseminated disease in patients who have undergone organ or hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/67\">",
"     67",
"    </a>",
"    ]. Disease can be caused by primary infection, reactivation of latent infection in the transplant recipient, or reactivation of infection transmitted in the donated organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective hospital-based study, adenoviral infections were compared between pediatric HCT and solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/76\">",
"     76",
"    </a>",
"    ]. Infection occurred at a median of 1.6 months post-transplantation consistent with reactivation disease. All deaths from adenoviral disease occurred exclusively among HCT recipients, likely related to their more severe immune dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviral diseases are well characterized in hematopoietic cell transplant (HCT) recipients. A wide range of clinical syndromes has been reported, including pneumonia, colitis, hepatitis, hemorrhagic cystitis, tubulointerstitial nephritis, encephalitis, and disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/67,77-80\">",
"     67,77-80",
"    </a>",
"    ]. In addition to the common lower serotypes, there was a preponderance of subgroup B types 11, 34, and 35, which are infrequent isolates in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 1050 adult HCT recipients, 51 (4.8 percent) shed adenoviruses and 10 (0.9 percent) had invasive adenoviral disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/77\">",
"     77",
"    </a>",
"    ]. Another report documented a higher incidence of adenoviral infection and disease in a HCT patient population (both children and adults) treated with T cell-depleted bone marrow grafts and more intensive immunosuppressive regimens; 42 of 210 patients (20.9 percent) had evidence of infection, while 13 (6.5 percent) developed invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/78\">",
"     78",
"    </a>",
"    ]. Adenoviral infections occurred more frequently and appeared earlier post-transplant in pediatric patients. Treatment and outcomes of adenovirus infections in adult HCT recipients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis and treatment of adenovirus infection\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenoviruses cause more frequent disease in pediatric HCT recipients compared to adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. In one study of 204 pediatric HCT recipients, 31 had adenovirus infections (15.1 percent) and 18 (8.8 percent) developed severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/81\">",
"     81",
"    </a>",
"    ]. Allogeneic recipients and, in particular, recipients of unrelated or mismatched related grafts had an increased risk of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the HCT population, adenoviral disease typically involves the donor organ in solid organ transplant recipients. As an example, the primary clinical manifestation in those who have undergone renal transplantation is acute hemorrhagic cystitis, sometimes complicated by interstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/63\">",
"     63",
"    </a>",
"    ]. This syndrome is almost exclusively associated with subgroup B types 11, 34, and 35. The incidence has not been well defined but is low. The prognosis is generally good, although infection occasionally results in fatal disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, adenoviral pneumonia is described as an early complication following lung transplantation. In one study of 308 lung transplant recipients, 4 (1.3 percent) developed adenovirus pneumonia, 3 of whom were children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common manifestation of invasive adenoviral disease is hepatitis in pediatric patients who have undergone liver transplantation. In one large study of 484 liver transplant recipients, 14 patients (three percent) developed adenovirus hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/84\">",
"     84",
"    </a>",
"    ]. Adenovirus type 5 was the most common isolate; types 1 and 2 also were identified. Six of 14 patients (43 percent) died; four recovered with a decrease in immunosuppressive therapy, while four other survivors required retransplantation. In another study, examination of pre- and post-transplant sera from recipients and donors suggested that latent virus was transmitted with the donated organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/13\">",
"     13",
"    </a>",
"    ]. Biopsies of small bowel transplants have also yielded a high incidence of adenovirus isolates. Progression of the infection and systemic dissemination have been associated with intensive immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of pediatric cardiac transplant recipients, adenoviruses were implicated as a cause of graft loss and coronary vasculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/86\">",
"     86",
"    </a>",
"    ]. Adenovirus was detected by polymerase chain reaction (PCR) in myocardial biopsies from 24 of 149 patients (16 percent) and was associated with reduced graft survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Congenital immunodeficiency syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary adenoviral infections can cause severe disease that is frequently fatal in children with immunodeficiency syndromes such as severe combined immunodeficiency disease (SCID). In patients with SCID, subgroup A type 31 and several subgroup B and C types have been associated with fatal pneumonia and hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/59,87\">",
"     59,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of unusual adenovirus serotypes have been isolated from HIV-infected patients. The most common urine isolates are subgroup B types 11, 34, and 35, with several intermediate strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The subgroup D adenoviruses are the predominant isolates from stool samples, including eight new serotypes, 43 through 49 and 51 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the frequency with which they are found in stool or urine specimens, adenoviruses are an uncommon cause of morbidity or mortality in HIV-infected patients. The viruses have been documented by histopathology or electron microscopy in colonic biopsies in some patients with chronic diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/91\">",
"     91",
"    </a>",
"    ]. However, the diarrhea may improve with treatment of other pathogens.",
"   </p>",
"   <p>",
"    Fatal cases of adenovirus infection in AIDS patients have been reported. For example, fatal hepatic necrosis has been documented in pediatric AIDS patients due to adenovirus types 1, 2, and 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/92\">",
"     92",
"    </a>",
"    ]. In the same review, a case of fatal adenovirus type 3 pneumonia complicated by hepatitis and encephalitis was described in an adult AIDS patient. Other reports include cases of adenoviral encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/93\">",
"     93",
"    </a>",
"    ] and necrotizing tubulointerstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438993\">",
"    <span class=\"h1\">",
"     POSSIBLE ASSOCIATION WITH OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cross-sectional study of 124 children and adolescents aged 8 to 18 years, antibodies to the subgroup D adenovirus type 36 were found in 19 individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/21/39257/abstract/95\">",
"     95",
"    </a>",
"    ]. Fifteen (78 percent) of the 19 seropositive individuals were obese (body-mass index [BMI] &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile), and antibodies against adenovirus 36 were found significantly more frequently among obese individuals than non-obese individuals (22 versus 7 percent). Among the obese children, those who were seropositive for adenovirus type 36 had a higher weight, BMI, waist circumference, and waist-height ratio than those who were seronegative. Although these results suggest a possible link between adenovirus type 36 seropositivity and obesity, they do not establish a causal relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13426?source=see_link\">",
"       \"Patient information: Adenovirus infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2583283\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenoviruses are a family of viruses that are an important cause of febrile illnesses in young children. They are most frequently associated with upper respiratory tract syndromes such as pharyngitis or coryza, but can also cause pneumonia. Less commonly, adenoviruses cause gastrointestinal, ophthalmologic, genitourinary, and neurologic diseases. Most adenoviral diseases are self-limiting, although fatal infections can occur in immunocompromised hosts and occasionally in healthy children and adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenoviruses have a double-stranded DNA genome of approximately 35 kb surrounded by a nonenveloped icosahedron with fiber-like projections. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virion structure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenoviruses have a worldwide distribution and infections occur throughout the year. Most individuals have serologic evidence of prior adenoviral infection by the age of 10. Adenovirus infections are prevalent in daycare centers and in households with young children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many epidemics of adenoviral disease have been described, including pharyngoconjunctival fever in summer camps and in association with public swimming pools, keratoconjunctivitis in medical facilities, and serious acute respiratory disease in military recruits. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over 50 human adenovirus serotypes have been identified based upon antigenic determinants detected by viral neutralization assay. Serotypes are further classified into six subgroups, A to F. Serotypes within each subgroup frequently share similar biologic properties. As examples, subgroup B types 11, 34, and 35 cause hemorrhagic cystitis, whereas subgroup D types 8, 19, and 37 are associated with keratoconjunctivitis (",
"      <a class=\"graphic graphic_table graphicRef63104 \" href=\"mobipreview.htm?34/24/35211\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenovirus 14 is a subgroup B serotype that was first identified in military recruits in the Netherlands in 1955. It subsequently emerged in the United States in 2005 as a cause of outbreaks of severe respiratory illness in military recruits and civilians. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adenovirus 14'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of adenoviral disease vary according to the age and immunocompetence of the host (",
"      <a class=\"graphic graphic_table graphicRef75951 \" href=\"mobipreview.htm?25/27/26043\">",
"       table 2",
"      </a>",
"      ). Severe disease has been associated primarily with subgroups B and C serotypes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide range of clinical syndromes has been reported in hematopoietic cell transplant (HCT) recipients, including pneumonia, colitis, hepatitis, hemorrhagic cystitis, tubulointerstitial nephritis, encephalitis, and disseminated disease. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to the HCT population, adenoviral disease typically involves the donor organ in solid organ transplant recipients. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Solid organ transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/1\">",
"      Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72:7909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/2\">",
"      Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77:9183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/3\">",
"      Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/4\">",
"      Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/5\">",
"      Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1977; 105:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/6\">",
"      Foy HM, Cooney MK, Hatlen JB. Adenovirus type 3 epidemic associated with intermittent chlorination of a swimming pool. Arch Environ Health 1968; 17:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/7\">",
"      Birenbaum E, Linder N, Varsano N, et al. Adenovirus type 8 conjunctivitis outbreak in a neonatal intensive care unit. Arch Dis Child 1993; 68:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/8\">",
"      Dingle JH, Langmuir AD. Epidemiology of acute, respiratory disease in military recruits. Am Rev Respir Dis 1968; 97:Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/9\">",
"      Kolavic-Gray SA, Binn LN, Sanchez JL, et al. Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Clin Infect Dis 2002; 35:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/10\">",
"      Montone KT, Furth EE, Pietra GG, Gupta PK. Neonatal adenovirus infection: a case report with in situ hybridization confirmation of ascending intrauterine infection. Diagn Cytopathol 1995; 12:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/11\">",
"      Pinto A, Beck R, Jadavji T. Fatal neonatal pneumonia caused by adenovirus type 35. Report of one case and review of the literature. Arch Pathol Lab Med 1992; 116:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/12\">",
"      Osamura T, Mizuta R, Yoshioka H, Fushiki S. Isolation of adenovirus type 11 from the brain of a neonate with pneumonia and encephalitis. Eur J Pediatr 1993; 152:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/13\">",
"      Koneru B, Atchison R, Jaffe R, et al. Serological studies of adenoviral hepatitis following pediatric liver transplantation. Transplant Proc 1990; 22:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/14\">",
"      Gray GC, McCarthy T, Lebeck MG, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis 2007; 45:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/16\">",
"      Russell KL, Broderick MP, Franklin SE, et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting. J Infect Dis 2006; 194:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/17\">",
"      Metzgar D, Osuna M, Kajon AE, et al. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J Infect Dis 2007; 196:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/18\">",
"      Binn LN, Sanchez JL, Gaydos JC. Emergence of adenovirus type 14 in US military recruits--a new challenge. J Infect Dis 2007; 196:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/19\">",
"      Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008; 26:2890.",
"     </a>",
"    </li>",
"    <li>",
"     Adenovirus type 4 and type 7 live oral vaccine prescribing information. file://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdf (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Acute respiratory disease associated with adenovirus serotype 14--four states, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of adenovirus 14 respiratory illness--Prince of Wales Island, Alaska, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/23\">",
"      Esposito DH, Gardner TJ, Schneider E, et al. Outbreak of pneumonia associated with emergent human adenovirus serotype 14--Southeast Alaska, 2008. J Infect Dis 2010; 202:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/24\">",
"      Lewis PF, Schmidt MA, Lu X, et al. A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. J Infect Dis 2009; 199:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/25\">",
"      Tate JE, Bunning ML, Lott L, et al. Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. J Infect Dis 2009; 199:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/26\">",
"      Vento TJ, Prakash V, Murray CK, et al. Pneumonia in military trainees: a comparison study based on adenovirus serotype 14 infection. J Infect Dis 2011; 203:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/27\">",
"      Trei JS, Johns NM, Garner JL, et al. Spread of adenovirus to geographically dispersed military installations, May-October 2007. Emerg Infect Dis 2010; 16:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/28\">",
"      Yun HC, Prakash V. Transmission of adenovirus serotype 14 in the health care setting. Clin Infect Dis 2008; 46:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/29\">",
"      Lessa FC, Gould PL, Pascoe N, et al. Health care transmission of a newly emergent adenovirus serotype in health care personnel at a military hospital in Texas, 2007. J Infect Dis 2009; 200:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/30\">",
"      Louie JK, Kajon AE, Holodniy M, et al. Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis 2008; 46:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/31\">",
"      Kajon AE, Lu X, Erdman DD, et al. Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States. J Infect Dis 2010; 202:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/32\">",
"      Centers for Disease Control (CDC). Adenovirus type 7 outbreak in a pediatric chronic-care facility--Pennsylvania, 1982. MMWR Morb Mortal Wkly Rep 1983; 32:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/33\">",
"      Straube RC, Thompson MA, Van Dyke RB, et al. Adenovirus type 7b in a children's hospital. J Infect Dis 1983; 147:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/34\">",
"      de Silva LM, Colditz P, Wadell G. Adenovirus type 7 infections in children in New South Wales, Australia. J Med Virol 1989; 29:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/35\">",
"      Porter JD, Teter M, Traister V, et al. Outbreak of adenoviral infections in a long-term paediatric facility, New Jersey, 1986/87. J Hosp Infect 1991; 18:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/36\">",
"      Mitchell LS, Taylor B, Reimels W, et al. Adenovirus 7a: a community-acquired outbreak in a children's hospital. Pediatr Infect Dis J 2000; 19:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/37\">",
"      Becroft DM. Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children. J Clin Pathol 1971; 24:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/38\">",
"      Edwards KM, Thompson J, Paolini J, Wright PF. Adenovirus infections in young children. Pediatrics 1985; 76:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/39\">",
"      Pacini DL, Collier AM, Henderson FW. Adenovirus infections and respiratory illnesses in children in group day care. J Infect Dis 1987; 156:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/40\">",
"      Dominguez O, Rojo P, de Las Heras S, et al. Clinical presentation and characteristics of pharyngeal adenovirus infections. Pediatr Infect Dis J 2005; 24:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/41\">",
"      Sarkkinen H, Ruuskanen O, Meurman O, et al. Identification of respiratory virus antigens in middle ear fluids of children with acute otitis media. J Infect Dis 1985; 151:444.",
"     </a>",
"    </li>",
"    <li>",
"     Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Diseases, 6, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.288.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/43\">",
"      Tabain I, Ljubin-Sternak S, Cepin-Bogovi�� J, et al. Adenovirus respiratory infections in hospitalized children: clinical findings in relation to species and serotypes. Pediatr Infect Dis J 2012; 31:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/44\">",
"      Chuang Yu, Chiu CH, Wong KS, et al. Severe adenovirus infection in children. J Microbiol Immunol Infect 2003; 36:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/45\">",
"      Carballal G, Videla C, Misirlian A, et al. Adenovirus type 7 associated with severe and fatal acute lower respiratory infections in Argentine children. BMC Pediatr 2002; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/46\">",
"      Lang WR, Howden CW, Laws J, Burton JF. Bronchopneumonia with serious sequelae in children with evidence of adenovirus type 21 infection. Br Med J 1969; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/47\">",
"      Levy Y, Nitzan M, Beharab A, et al. Adenovirus type 3 infection with systemic manifestation in apparently normal children. Isr J Med Sci 1986; 22:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/48\">",
"      Simil&auml; S, Jouppila R, Salmi A, Pohjonen R. Encephaloningitis in children associated with an adenovirus type 7 epidemic. Acta Paediatr Scand 1970; 59:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/49\">",
"      Wadell G, Vars&aacute;nyi TM, Lord A, Sutton RN. Epidemic outbreaks of adenovirus 7 with special reference to the pathogenicity of adenovirus genome type 7b. Am J Epidemiol 1980; 112:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/50\">",
"      Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/51\">",
"      Castro-Rodriguez JA, Daszenies C, Garcia M, et al. Adenovirus pneumonia in infants and factors for developing bronchiolitis obliterans: a 5-year follow-up. Pediatr Pulmonol 2006; 41:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/52\">",
"      Colom AJ, Teper AM, Vollmer WM, Diette GB. Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis. Thorax 2006; 61:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/53\">",
"      Azar MJ, Dhaliwal DK, Bower KS, et al. Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol 1996; 121:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/54\">",
"      Uhnoo I, Wadell G, Svensson L, Johansson ME. Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children. J Clin Microbiol 1984; 20:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/55\">",
"      Van R, Wun CC, O'Ryan ML, et al. Outbreaks of human enteric adenovirus types 40 and 41 in Houston day care centers. J Pediatr 1992; 120:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/56\">",
"      Yolken RH, Lawrence F, Leister F, et al. Gastroenteritis associated with enteric type adenovirus in hospitalized infants. J Pediatr 1982; 101:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/57\">",
"      Krajden M, Brown M, Petrasek A, Middleton PJ. Clinical features of adenovirus enteritis: a review of 127 cases. Pediatr Infect Dis J 1990; 9:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/58\">",
"      Bines JE, Liem NT, Justice FA, et al. Risk factors for intussusception in infants in Vietnam and Australia: adenovirus implicated, but not rotavirus. J Pediatr 2006; 149:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/59\">",
"      South MA, Dolen J, Beach DK, Mirkovic RR. Fatal adenovirus hepatic necrosis in severe combined immune deficiency. Pediatr Infect Dis 1982; 1:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/60\">",
"      Mufson MA, Belshe RB. A review of adenoviruses in the etiology of acute hemorrhagic cystitis. J Urol 1976; 115:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/61\">",
"      Harnett GB, Phillips PA, Gollow MM. Association of genital adenovirus infection with urethritis in men. Med J Aust 1984; 141:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/62\">",
"      Swenson PD, Lowens MS, Celum CL, Hierholzer JC. Adenovirus types 2, 8, and 37 associated with genital infections in patients attending a sexually transmitted disease clinic. J Clin Microbiol 1995; 33:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/63\">",
"      Ito M, Hirabayashi N, Uno Y, et al. Necrotizing tubulointerstitial nephritis associated with adenovirus infection. Hum Pathol 1991; 22:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/64\">",
"      Akiyama H, Kurosu T, Sakashita C, et al. Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Clin Infect Dis 2001; 32:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/65\">",
"      Frange P, Peffault de Latour R, Arnaud C, et al. Adenoviral infection presenting as an isolated central nervous system disease without detectable viremia in two children after stem cell transplantation. J Clin Microbiol 2011; 49:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/66\">",
"      Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis 1998; 27:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/67\">",
"      Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/68\">",
"      Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994; 90:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/69\">",
"      Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/70\">",
"      Wright J, Couchonnal G, Hodges GR. Adenovirus type 21 infection. Occurrence with pneumonia, rhabdomyolysis, and myoglobinuria in an adult. JAMA 1979; 241:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/71\">",
"      Meshkinpour H, Vaziri ND. Association of myoglobinuria with adenovirus infection. West J Med 1982; 137:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/72\">",
"      Rahal JJ, Millian SJ, Noriega ER. Coxsackievirus and adenovirus infection. Association with acute febrile and juvenile rheumatoid arthritis. JAMA 1976; 235:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/73\">",
"      Fraser KJ, Clarris BJ, Muirden KD, et al. A persistent adenovirus type 1 infection in synovial tissue from an immunodeficient patient with chronic, rheumatoid-like polyarthritis. Arthritis Rheum 1985; 28:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/74\">",
"      Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003; 13:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/75\">",
"      Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76:10608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/76\">",
"      de Mezerville MH, Tellier R, Richardson S, et al. Adenoviral infections in pediatric transplant recipients: a hospital-based study. Pediatr Infect Dis J 2006; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/77\">",
"      Shields AF, Hackman RC, Fife KH, et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/78\">",
"      Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/79\">",
"      Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/80\">",
"      Vyas JM, Marasco WA. Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis 2012; 2012:463569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/81\">",
"      Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/82\">",
"      Myerowitz RL, Stalder H, Oxman MN, et al. Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med 1975; 59:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/83\">",
"      Ohori NP, Michaels MG, Jaffe R, et al. Adenovirus pneumonia in lung transplant recipients. Hum Pathol 1995; 26:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/84\">",
"      Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992; 165:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/85\">",
"      Pinchoff RJ, Kaufman SS, Magid MS, et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 2003; 76:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/86\">",
"      Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/87\">",
"      Johansson ME, Brown M, Hierholzer JC, et al. Genome analysis of adenovirus type 31 strains from immunocompromised and immunocompetent patients. J Infect Dis 1991; 163:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/88\">",
"      Horwitz MS, Valderrama G, Hatcher V, et al. Characterization of adenovirus isolates from AIDS patients. Ann N Y Acad Sci 1984; 437:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/89\">",
"      Hierholzer JC, Wigand R, Anderson LJ, et al. Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). J Infect Dis 1988; 158:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/90\">",
"      De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999; 37:3940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/91\">",
"      Maddox A, Francis N, Moss J, et al. Adenovirus infection of the large bowel in HIV positive patients. J Clin Pathol 1992; 45:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/92\">",
"      Krilov LR, Rubin LG, Frogel M, et al. Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states. Rev Infect Dis 1990; 12:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/93\">",
"      Anders KH, Park CS, Cornford ME, Vinters HV. Adenovirus encephalitis and widespread ependymitis in a child with AIDS. Pediatr Neurosurg 1990; 16:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/94\">",
"      Shintaku M, Nasu K, Ito M. Necrotizing tubulo-interstitial nephritis induced by adenovirus in an AIDS patient. Histopathology 1993; 23:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/21/39257/abstract/95\">",
"      Gabbert C, Donohue M, Arnold J, Schwimmer JB. Adenovirus 36 and obesity in children and adolescents. Pediatrics 2010; 126:721.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8339 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.80-F9E9CAA6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39257=[""].join("\n");
var outline_f38_21_39257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2583283\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIRION STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serotype prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Military recruits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adenovirus 14",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pharyngitis and coryza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Otitis media and less common presentations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acute respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Disseminated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      INFECTIONS IN IMMUNOCOMPROMISED HOSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Congenital immunodeficiency syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5438993\">",
"      POSSIBLE ASSOCIATION WITH OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2583283\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/24/35211\" title=\"table 1\">",
"      Adenovirus serotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/27/26043\" title=\"table 2\">",
"      Adenoviral syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/52/26441?source=related_link\">",
"      Adenovirus pathogenesis and vector applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13426?source=related_link\">",
"      Patient information: Adenovirus infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=related_link\">",
"      Viral myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_21_39258="ECG pace mapping RVOT tachycardia";
var content_f38_21_39258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68142%7ECARD%2F79938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68142%7ECARD%2F79938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) during electrophysiologic study showing pace mapping of an idiopathic RVOT tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: 12 lead ECG of spontaneous ventricular tachycardia (VT) in a patient with a structurally normal heart. The VT has a left bundle branch block (LBBB) and an inferior axis morphology, suggesting that the origin is in the right ventricular outflow tract (RVOT). Right panel: A mapping catheter has been positioned in the RVOT and pacing is performed from its tip during sinus rhythm. The \"pace map\" closely approximates the QRS morphology of the spontaneous VT in all 12 leads, suggesting that the mapping catheter is at or near the VT focus.",
"    <div class=\"footnotes\">",
"     S: pacing stimulus artifact.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing pace map of ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 657px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The QRS complexes on the twelve-lead ECG, recorded during spontaneous ventricular tachycardia (VT) provoked by isoproterenol, are identical in each lead to those recorded during ventricular pacing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39258=[""].join("\n");
var outline_f38_21_39258=null;
var title_f38_21_39259="Acute bleeding EVL vs ES";
var content_f38_21_39259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Control of acute variceal bleeding - endoscopic variceal ligation versus endoscopic sclerotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        EVL, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        ES, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jensen 1993",
"       </td>",
"       <td>",
"        10/14 (71)",
"       </td>",
"       <td>",
"        10/11 (91)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laine 1993",
"       </td>",
"       <td>",
"        8/9 (89)",
"       </td>",
"       <td>",
"        8/9 (89)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lo 1995",
"       </td>",
"       <td>",
"        17/18 (94)",
"       </td>",
"       <td>",
"        12/15 (80)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiegman 1992",
"       </td>",
"       <td>",
"        12/14 (86)",
"       </td>",
"       <td>",
"        10/13 (77)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarin 1997",
"       </td>",
"       <td>",
"        47/59 (80)",
"       </td>",
"       <td>",
"        48/56 (86)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hou 1995",
"       </td>",
"       <td>",
"        20/20 (100)",
"       </td>",
"       <td>",
"        14/16 (88)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gimson 1993",
"       </td>",
"       <td>",
"        54/59 (91)",
"       </td>",
"       <td>",
"        49/53 (92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chen 1995",
"       </td>",
"       <td>",
"        11/12 (91)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lo 1997",
"       </td>",
"       <td>",
"        37/37 (100)",
"       </td>",
"       <td>",
"        34/38 (89)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total",
"       </td>",
"       <td>",
"        216/242 (89)",
"       </td>",
"       <td>",
"        185/211 (88)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39259=[""].join("\n");
var outline_f38_21_39259=null;
var title_f38_21_39260="Definitions of test accuracy";
var content_f38_21_39260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Definition of sensitivity, specificity, and predictive values",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 188px; background-image: url(data:image/gif;base64,R0lGODlhLwG8AMQAAP///wAAAICAgIiIiFVVVREREczMzDMzM+7u7qqqqnd3dyIiIkRERGZmZpmZmd3d3bu7u6CgoODg4AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAvAbwAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVdAMFAQEKBjQKAQMAmQgAn6EmpgYBB1YEAQljCZqzAQaus6dREAEEIwYHmr0Av8FNssINuTWjLqqsVa6wZAgBBSPRAAyvUcC8IwsFCAObAODi5EvjB5wj45qhnwyZvcSaBuMDt5v4nw0A+PgyaUqQqVOBBSeoFQC24AEABwuKfSJQQAECfQkualqQsZq2AvdmPaPRbZaCIwqv/20zZSQeAnCdSKgS5mzYqpo1lyDQpqlAgnEnIz5gWRCYg3agRAUghQ9BAWvg/oHK+UmBg6QmUl5lULNBAAefNClwlSvagwALUo7rhW1aNZWwgMUs4jWTNJneAByzeWBvzib5AjDQN5Cl3KuaDpwLxQwfAFdeT+LLqWqBPFJZ3zpzZ5KlUsxKaaXc23ZMShH6FhxFqYnBiZkicN5cxZeJAosPAyTTTcJwrRFGHWdy6HiXPakDKqvknS3cCLW8/pbCSlblagCjvbm6TpIWuiKnH29T4ioi99h5y4UDqv7cySUJwjLnXMu3AYG8HbtT4BgAMGGO3QKLLL+JIowICmXCAP8pEOHimUYDQVhNdvRkMlIY4ZV2RD8vBQABCSX9Vg9N3RwIiCyuAbDLXNi9ZcmLUmgjzQAXtmgNHhIIoOOOPPbo449ABqljBDAW2UKOQiap5JJEGunkk1BGKaUk8vUUGlrniTAOaL54Z8uE/hU45Zh6pTfKS86VsKUJ0t3Si1xkkrmXCMzAqeZSbNKmknl2xinlnJ89cBAJ1HhnoiqzWBPNQRGx6OeTgOLH1QlrltBmLZw5+qiRkeKZQqV4XehKJ91ouimMnXJpAqhdiiricafGKuustNZq66245qrrrrz26uuvwAYr7LDEFmvsscgmq+yyzDbr7LPJIqYMtIJgIpb/qS3AOWh4INYinRTMjBEiL+7A4hkUuxw4YmwlGpNXMjdQU2MK30YRLhmeuYPQuU60K4I57AH8XRLqsFPmAQpqiQt2GI2Kn1PWSJiAw7PIglC6J8iCsGAKvzMdRRZhZABPDDyg0EdfinXDuO8VkS9auvErhEswWZqXbAfgzMROiSawl1cDBBzAA9Wh5q2eT4lX1tHPAJOAVx+a8DMoQg9lUtHtXdUAdL3cO8bLNAqGFV3VjIeXMH6tkva8BLvCwF5AEfbKvaPmlDTdTCtMEdtl9hK3d/FhFS6iIlH4mRlgGzc2EYWmaDNNtDmj8xK3MajbXtoEzZzRSxtgt6Jj143W/zearLYQCZhTvfl0p2ANjkMIvrXXcDiwvCFWjoU1rRDlfZXngQIHtd7ASASuiT+yCOSPVLMYILHozyT9/G8CToeQiosnf3zH9jwoMk+8GL5fGWD/u/jMunUYtQghdrLuMP5KASgS+V4/wvzUmoG/EU9hxkDLItgfHZC0pAIacEdNyt8cCHjABiYpgQqMoAQnOMEqvcVCNqKUp/BCi5DMggCqomAcOgUKbiElhNJhD3tESIdIHQQkLroTCvWksJMIkIVtcOFWYtgiQ3HQSuwBGg7n4MJsWGlVG2wVCeizuyHm0EwRy8SNZJinC63QiUSEosKmuMQkoseKxMOiGMdIxv8ymvGMaEyjGtfIxja68Y1wjKMc50jHOtrxjnjMox5X4LU9zoBwgsFWCVKCjRsCYRQyq02YBInHmuyCbynQEBL6GCo/qqAmWhGIMOTTtQJwJme8sBj2/Law+60iYRo7ACs4EwqePWUp+jEJfiZWC6MY0XMkg50ca3IVAtQEKBojQdKwARtgQABqVTNlL4BGoFVUrTqjAEh6cjIqFJ3FNebQGh0BCUL2aIxnHhvmNmAzjgacTm53gdsm5oRObcESFKWh5m8i4pUEAJKGcZTOL78jSnEeBTahCUU5M+aNzM1poCOQ0Wekqa7RiacT+vpXAXS5TXw+RHnMU5sorHGf2Wz/0qEZFZP2eAMo+hjgARHZ2GIyehIBjQo7mTjFyD5oySMYsqZyuClOd8rTnsIgaT61A1C1cMU+NLN5hGkiEzDGrmLAz6lZGGoWiuqHDG1DoVCIX/DaQ9Uj2FIbKROMQ5ImF1VE7BYcQQEwugGLmYo1las0SUZD8Z93ADKETLCdEaxqrvMFgWYgedwX+TI5JViTYyphjDXK+hazgLQEchEUVMKhtWYeYC1ICcrQjLkLa3SVD3xd5BHqYrYuoc0bzlhbE+i5jQFERGVkPZo18KMJvLrznn3JS2naWQvoALCqMUxNloTQuNfcLHKzYUW9jhBRs0rlJLG1Z2N9l9A0sa8W/7tAyOuUqTekLO+6znsLQqWgV/AEt7RH6F2WAMpVcmx1ZzE12irIkTQCfYRhiTIQZMu2APeBjwAllatJ5ZISBHQDr3kIbRI4FJH1hal5T71Z/NCwov0yMqhjoJEJ+iQJBjrwwz6CIIaF4GEQm1gAIh6xilecx3ERgD4gPEFFTkAYX9JiUixeMO7I8dkZmyCetHlkjnV8Cm+mR5i/NdpdMMnDIRPhZScR4ggsKCbx4IKXR3byEF5WShP4uARA/iCCtewDKPMxyeJZskXJ/OQdoxnJNDbbctlM5zrb+c54zrOe98znPvv5z4AOtKAHTehCG/rQYJDkihFlwyzDgD0mHP9CNATIjETakXAG0KkKPlsERQvTi3usjNpQm0sr2wWQyRFN/2g3qAYdWSEMMZlHluJqZPTkFbBx9QH0wR9Q9AM5EEqrG2fiFW30Ipu6wSyQPYuOpJniKqlmhVeuoxXBFMoetJm2snEdnVWApjElTFpUHGs/Ns6kQ92mxa6TYhbCuIdOHEXLZejznZQ44zT0vg27uf3igYE7FJChr3fGXEbYEOjYE82sEWnJmHcuD6g8oceaM7iW06SQHDKayb1HQLviQHg7u9QtqcX8Ead1VKUGri1QCRQTV48tQdYOj8tDUXJ+P+S1cd0HVv6DIH1w0ZIdougOIo3oFFy7AMPNAdH/i870pkdCqk53AtSvwGk8uLhcrJMCUyNMIqhiYepWqHoeuLwvvy5Bq8MT3rvP7juw6qNkG12kc4N9l/2ydRi5hCtL5xqmW6R6FgRHQnnbXGSYNcDSPwCsowCKs8Im4bCOU1rcGQu6BJyl3N06qbgpezmRYLaG5dishzr7XEGADRiZG23Z6o6e00o8t69frW5a+1r6Lla2V6rtCW7rHdgreTkVI7B4w8iHxHWZca0xLuSUm1xFpmMjNmE2dG8vXdBx5zKZz656dHnQ9Ix3kdD5Lje88+bE7xgeHjOCen/3jbS3t/yMi6+VgTH9MontrPktgInClIn+4v2DAaYyA9Zbt2+RcqCmB+UTekpVZunTYN0CYe/zPmlQYZkXdUigYRZWCSV2Yh+WYkW3gRzYQB5ogSRYgqDlHfAEJhzGcWhWY4zWNyZYgVb2JlXGgnGmZvagaUVnJ+q1gnTSgnIGM74Xg+ClZIxSZVTGIklFbGKzfyXIg5gCYV4GhGoGQq/lhCQIhaQCKyXwZSQAZL1wcERYhA9lEzX4gzdoWkaDhWPYhm74hnAYh3I4h3RYh3Z4h3iYh3q4h1QQAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TN (true negative): negative exercise ECG and negative angiogram; TP (true positive): positive exercise ECG and positive angiogram; FM (false negative): negative exercise ECG and positive angiogram; FP (false positive): positive exercise ECG and negative angiogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39260=[""].join("\n");
var outline_f38_21_39260=null;
var title_f38_21_39261="Risk factors stillbirth";
var content_f38_21_39261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimates of maternal risk factors and risk of stillbirth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Prevalence, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Estimated rate of stillbirth, per 1000 total births",
"      </td>",
"      <td class=\"subtitle1\">",
"       Odds ratio",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       All pregnancies",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       6.4",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low risk pregnancies",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       4.0-5.5",
"      </td>",
"      <td>",
"       0.86",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nulliparity",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       7-8",
"      </td>",
"      <td>",
"       1.2-3.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Hypertensive disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chronic hypertension",
"      </td>",
"      <td class=\"sublist_other\">",
"       6-10",
"      </td>",
"      <td class=\"sublist_other\">",
"       6-25",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.5-2.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\">",
"       Pregnancy induced hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Mild",
"      </td>",
"      <td class=\"sublist_other\">",
"       5.8-7.7",
"      </td>",
"      <td class=\"sublist_other\">",
"       9-51",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.2-4.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Severe",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.3-3.3",
"      </td>",
"      <td class=\"sublist_other\">",
"       12-29",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.8-4.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Treated with diet",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.5-5",
"      </td>",
"      <td class=\"sublist_other\">",
"       6-10",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.2-2.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Treated with insulin",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.4",
"      </td>",
"      <td class=\"sublist_other\">",
"       6-35",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.7-7.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic lupus erythematosus",
"      </td>",
"      <td>",
"       &lt;1",
"      </td>",
"      <td>",
"       40-150",
"      </td>",
"      <td>",
"       6-20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal disease",
"      </td>",
"      <td>",
"       &lt;1",
"      </td>",
"      <td>",
"       15-200",
"      </td>",
"      <td>",
"       2.2-30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thyroid disorders",
"      </td>",
"      <td>",
"       0.2-2",
"      </td>",
"      <td>",
"       12-20",
"      </td>",
"      <td>",
"       2.2-3.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombophilia",
"      </td>",
"      <td>",
"       1-5",
"      </td>",
"      <td>",
"       18-40",
"      </td>",
"      <td>",
"       2.8-5.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cholestasis of pregnancy",
"      </td>",
"      <td>",
"       &lt;0.1",
"      </td>",
"      <td>",
"       12-30",
"      </td>",
"      <td>",
"       1.8-4.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Smoking &gt;10 cigarettes",
"      </td>",
"      <td>",
"       10-20",
"      </td>",
"      <td>",
"       10-15",
"      </td>",
"      <td>",
"       1.7-3.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Obesity (prepregnancy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       BMI 25-29.9 kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </td>",
"      <td class=\"sublist_other\">",
"       21",
"      </td>",
"      <td class=\"sublist_other\">",
"       12-15",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.9-2.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       BMI &gt;30",
"      </td>",
"      <td class=\"sublist_other\">",
"       20",
"      </td>",
"      <td class=\"sublist_other\">",
"       13-18",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.1-2.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low educational attainment (&lt;12 years vs. 12 years+)",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       10-13",
"      </td>",
"      <td>",
"       1.6-2.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous growth restricted infant (&lt;10 percent)",
"      </td>",
"      <td>",
"       6.7",
"      </td>",
"      <td>",
"       12-30",
"      </td>",
"      <td>",
"       2-4.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous cesarean section",
"      </td>",
"      <td>",
"       24-28",
"      </td>",
"      <td>",
"       6-13",
"      </td>",
"      <td>",
"       1.0-2.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous stillbirth",
"      </td>",
"      <td>",
"       0.5-1.0",
"      </td>",
"      <td>",
"       9-20",
"      </td>",
"      <td>",
"       1.4-3.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Multiple gestation",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       2-3.5",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Twins",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.7",
"      </td>",
"      <td class=\"sublist_other\">",
"       12",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.0-2.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Triplets",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.14",
"      </td>",
"      <td class=\"sublist_other\">",
"       34",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.8-3.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Advanced maternal age (reference &lt;35)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       35-39",
"      </td>",
"      <td class=\"sublist_other\">",
"       15-18",
"      </td>",
"      <td class=\"sublist_other\">",
"       11-14",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.8-2.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       40+",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       11-21",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.8-3.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Black compared to White",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       12-14",
"      </td>",
"      <td>",
"       2.0-2.2",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005; 193:1923.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39261=[""].join("\n");
var outline_f38_21_39261=null;
var title_f38_21_39262="Melatonin core body temp";
var content_f38_21_39262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Core body temperature profiles following melatonin or placebo treatment 30 minutes before bedtime",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 353px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhdanova IV, Wurtman RJ, Regan MM,&nbsp;et al. Melatonin Treatment for Age-Related Insomnia. J Clin Endocrinol Metab 2001; 86:4727. file://jcem.endojournals.org/.&nbsp;Copyright &copy; 2001 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39262=[""].join("\n");
var outline_f38_21_39262=null;
var title_f38_21_39263="Battery versus coin lateral radiograph";
var content_f38_21_39263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Battery versus coin ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlarged radiographic comparison between a camera battery ingestion (left) and coin ingestion (right) demonstrates the subtle, but characteristic differences. The bilaminar structure of the battery gives a \"step off\" appearance on the lateral view, whereas the coin has sharp, crisp edges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Barbara Specter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_21_39263=[""].join("\n");
var outline_f38_21_39263=null;
